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THE GARDEN STATE JUST GOT GREENER: NEW JERSEY IS 
THE FOURTEENTH STATE IN THE NATION TO LEGALIZE 
MEDICAL MARIJUANA 
 
Melissa Brown∗ 
I. INTRODUCTION 
On January 11, 2010, both houses of the New Jersey Legislature 
passed the New Jersey Compassionate Use Medical Marijuana Act 
(the NJCMA or the “Act”),
1
 making it the fourteenth state in the na-
tion to decriminalize the medical use of marijuana under state law.
2
  
 
 ∗ J.D., 2010, Seton Hall University School of Law; B.S., 2004, S.I. Newhouse 
School of Public Communications, Syracuse University.  I would like to thank Dean 
Kathleen Boozang, Seton Hall University School of Law, for her assistance in prepar-
ing this Comment.  I would also like to thank my husband, parents, and in-laws for 
supporting me through this endeavor.   
 1 Bills, NEW JERSEY STATE LEGISLATURE, 
http://www.njleg.state.nj.us/bills/bills0001.asp (click “Bills 2008-2009”; then select 
“Search by Bill Number”; then search for “S119”) (last visited Mar. 27, 2011).  On 
January 8, 2008, members of both houses of the New Jersey legislature introduced 
bills intended to legalize the medical use of marijuana via enactment of the NJCMA.  
Id.  The bills are General Assembly Bill 804 (A804 or “the Assembly bill”) and Senate 
Bill 119 (S119 or “the Senate bill”).  Id.  On December 15, 2008, S119 was reported 
out of the Senate Health, Human Services and Senior Citizens Committee with 
amendments.  Id.  On February 23, 2009, the Senate passed bill S119 with a vote of 
22–16, and three days later, the General Assembly received it and referred it to the 
Assembly Health and Senior Services Committee.  Id.  On June 4, 2009, the Senate 
bill was reported out of the Assembly Health and Senior Services Committee with 
amendments.  Id.  On January 7, 2010, the General Assembly further amended the 
Senate bill on the assembly floor.  Id.  On January 11, 2010, just over two years after 
the 2008–2009 legislative session when the medical-marijuana bills were introduced, 
the General Assembly passed Senate bill S119 (as amended by the General Assembly 
on January 7, 2010) with a vote of 48–14, and the Senate passed it with a vote of 25–
13.  Id.   
 2 See Active State Medical Marijuana Programs, NORML, 
http://norml.org/index.cfm?Group_ID=3391 (last visited Oct. 20, 2010).  In fact, 
medical-marijuana bills have been introduced in the New Jersey Legislature since 
2004.  See Gen. Assem. 804, 213th Leg., 2008–2009 Sess. (N.J. 2008); S. 119, 213th 
Leg., 2008–2009 Sess. (N.J. 2008); Gen. Assem. 933, 212th Leg., 2006–2007 Sess. (N.J. 
2006); S. 88, 212th Leg., 2006–2007 Sess. (N.J. 2006); Gen. Assem. 4501, 211th Leg., 
2004–2005 Sess. (N.J. 2004); S. 2200, 211th Leg., 2004–2005 Sess. (N.J. 2004); see also 
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Seven days later, then-Governor Jon S. Corzine signed the measure 
into law.
3
  Members of both major political parties introduced and 
supported the Act throughout the long legislative process,
4
 which 
signals that the legalization of medical marijuana and the desire to 
provide relief to people suffering from debilitating medical condi-
tions are not partisan issues. 
Despite the widely accepted therapeutic value of marijuana,
5
 
possession, use, or cultivation of the drug, even for medicinal pur-
poses, have been criminal offenses with harsh penalties under both 
federal and New Jersey law for many years.
6
  Additionally, as a Sche-
dule I controlled substance under the federal Controlled Substances 
Act (CSA),
7
 marijuana cannot be prescribed by a physician or distri-
buted by a pharmacy.
8
  In fact, the federal government continues to 
not only discourage but also hinder research on botanical medical 
marijuana.
9
 
Medicinal marijuana advocates have had success at the state lev-
el.  Between 1978 and 2008, thirty-six states and the District of Co-
lumbia enacted laws intended to provide suffering patients with legal 
 
Phillip Smith, New Jersey Medical Marijuana Bill Heads for Senate Floor After Favorable 
Committee Vote, DRUG WAR CHRONICLE (Dec. 19, 2008, 12:00 AM), 
http://stopthedrugwar.org/chronicle/2008/dec/19/feature_new_jersey_medical_m
arij.    
 3 New Jersey Gov. John Corzine Signs Medical Marijuana Bill into Law, N.Y. DAILY 
NEWS (Jan. 18, 2010), http://www.nydailynews.com/news/2010/01/18/2010-01-
18_new_jersey_gov_corzine_signs_.html.  Interestingly, while some have stated that 
Governor Chris Christie would have opposed the measure, others have reported that 
he supports medical marijuana.  Medical Marijuana Bill ‘Workable,’ N.J. Attorney General 
Says, NJ.COM (Apr. 21, 2009), 
http://www.nj.com/news/index.ssf/2009/04/medical_marijuana_bill_workabl.html 
[hereinafter Medical Marijuana Bill]; Brian Thompson, Stunning Reversal at Medical 
Marijuana Trial, NBC NEW YORK, (Dec. 16, 2009), 
http://www.nbcnewyork.com/news/local-beat/Stunner-at-Medial-Marijuana-Trial-in-
NJ-79447032.html.  
 4 See N.J. Gen. Assem. B. 804; N.J. S.B. 119; see also supra note 1.  
 5 See infra Part II. 
 6 See 21 U.S.C. §§ 841(a)(1), 844(a) (2006); see also N.J. STAT. ANN. §§ 2C:35-1 to -
29, 2C:36-1 to -10 (West 2010). 
 7 21 U.S.C. § 812 (2006); see also discussion infra Part III.A. 
 8 United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 491 (2001); see 
also 21 U.S.C. § 829 (2006) (detailing how drugs classified in Schedules II through V 
may be prescribed and dispensed). 
 9 See Gardiner Harris, Researchers Find Study of Medical Marijuana Discouraged, N.Y. 
TIMES, Jan. 19, 2010, at A14. 
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access to marijuana.
10
  In 1996, California became the first state to 
pass a law legalizing medical use of the drug, and twelve states fol-
lowed its lead.
11
  New Jersey is now the fourteenth state to remove 
state-level criminal penalties for medical marijuana and recognize its 
medicinal value.  The NJCMA carves out a limited but necessary ex-
emption from criminal liability for individuals who need marijuana to 
ease the symptoms of debilitating illnesses when other treatment op-
tions do not work. 
The NJCMA is among the most restrictive state medical-
marijuana laws in the nation and it was created to provide marijuana 
to individuals with specific enumerated debilitating medical condi-
tions
12
 via a reasonable system that is highly regulated and extensively 
overseen.
13
  New Jersey’s Attorney General at the time of passage, 
Anne Milgram, deemed the NJCMA to be “workable.”
14
  This is im-
portant because for the legislation to be effective, it must have the 
support of the state government and state and local law enforcement.  
Additionally, public opinion in New Jersey overwhelmingly supports 
the legalization of marijuana for medical use.
15
  According to a poll 
conducted in May 2006, eighty-six percent of voters were convinced 
that “seriously ill patients should have access to marijuana for medical 
purposes if a physician recommends it.”
16
  Significantly, fifty-nine per-
cent of New Jersey voters even said that they would defy current law 
 
 10 MARIJUANA POLICY PROJECT, STATE-BY-STATE MEDICAL MARIJUANA LAWS: HOW TO 
REMOVE THE THREAT OF ARREST 10 (2008), available at 
http://docs.mpp.org/pdfs/download-materials/SBSR_NOV2008_1.pdf. 
 11 See infra notes 154–55 and accompanying text.   
 12 See S. 119, 213th Leg., 2008–2009 Sess. (N.J. 2008) (as passed by both houses of 
the N.J. Legislature on Jan. 11, 2010). 
 13 See infra Part IV.  
 14 Medical Marijuana Bill, supra note 3.  Acknowledging existing concerns about 
ensuring that the law allows access to marijuana only to those with debilitating medi-
cal conditions, Attorney General Milgram’s office “sent recommendations to the 
governor on ways to guard against abuses.”  Id.  
 15 See THE POLLING COMPANY, INC., MEDICAL MARIJUANA: STATEWIDE SURVEY OF 700 
REGISTERED VOTERS OF NEW JERSEY 3 (June 2006), available at 
http://www.pollingcompany.com/cms/files/DPANJ%20Medical%20Marijuana%20
Executive%20Summary.pdf. 
 16 Id. at 3.  In fact, agreement on this issue “spanned demographic divides, with 
no less than three-quarters of every major demographic group studied, including 
members of all three political parties, endorsing access to medical marijuana with a 
doctor’s recommendation.”  Id.  at 4.  Further, when told that “the use of marijuana, 
including for medical reasons, is illegal in New Jersey [but] about 11 other states now 
allow seriously ill patients to have medical marijuana with a doctor’s recommenda-
tion . . . eighty-three percent indicated that patients in their own state should have 
the same rights.”  Id. 
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to obtain the drug for a “close friend or family member [who] was 
suffering from a condition that could be eased by marijuana.”
17
 
Finally, while federal policymakers remain ambivalent about the 
wisdom of state medical-marijuana legalization,
18
 the Obama adminis-
tration has taken a very different stance than previous administrations 
regarding federal drug enforcement in states that have legalized ma-
rijuana for medical use.
19
  Thus, now is the time for states like New 
Jersey to enact medical-marijuana legislation.  Ultimately, reason, 
compassion, and medical evidence support New Jersey’s elimination 
of criminal penalties for the medical use of marijuana under state 
law. 
Part II of this Comment reviews the history of marijuana as med-
icine and the science behind the controversy of whether marijuana 
has therapeutic value.  Part III provides a brief overview of marijua-
na’s current status under federal and state law and discusses the in-
terplay between the two.  In Part IV, this Comment provides an over-
view and critique of the NJCMA and suggests ways in which the Act 
can be improved. 
II. MARIJUANA AS MEDICINE 
A. Brief History of the Use of Marijuana for Medicinal Purposes 
Marijuana,
20
 also known as cannabis or hemp, is one of the old-
est known psychoactive plants on earth.
21
  Marijuana grows as both a 
weed and a cultivated plant all over the world.
22
  While it has only 
been used as a medicine in the United States since the middle of the 
1800s, marijuana has been used medicinally throughout the world for 
thousands of years.
23
  The first evidence of the medical use of mariju-
 
 17 Id. at 5.  Seventy-one percent of those who responded agreed “with the New 
Jersey state legislature passing a bill that would permit patients to possess ‘one ounce 
of marijuana and six marijuana plants for medical purposes if they have a recom-
mendation from a doctor,’ and forty-seven percent did so ‘strongly.’”  Id. at 6. 
 18 See Harris, supra note 9, at A1.  
 19 See infra Part III.C.2.  
 20 The word is alternatively spelled “marihuana,” most often in U. S. government 
literature.  Throughout this Comment, “marijuana,” “marihuana,” and “cannabis” 
may be used interchangeably to refer to the natural, botanical form of the substance.  
 21 LESTER GRINSPOON & JAMES BAKALER, MARIHUANA, THE FORBIDDEN MEDICINE 1 
(rev. ed. 1997).   
 22 Id. 
 23 Id. at 3–7.  “Cannabis may have been cultivated as long as ten thousand years 
ago” and “has long been used as a medicine in India, China, the Middle East, South-
east Asia, South Africa, and South America.”  Id. at 3.  In addition to its therapeutic 
properties, cannabis “fiber has been used to produce cloth and paper for centuries,” 
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ana was published five thousand years ago, recommending cannabis 
for “malaria, constipation, rheumatic pains, ‘absentmindedness,’ and 
female disorders.”
24
  Cannabis “did not come into its own” as a medi-
cine in the West “until the middle of the nineteenth century.”
25
  In 
1839, the first Western physician to take an interest in the medical 
properties of cannabis, W.B. O’Shaughnessy, wrote about the plant’s 
analgesic and muscle relaxant properties and called it “an anticonvul-
sive remedy of the greatest value.”
26
  Soon after, doctors in Europe 
and the United States started to recognize marijuana’s therapeutic 
potential and began prescribing cannabis “for a variety of physical 
conditions”; preparations made from cannabis were available in drug 
stores.
27
  Some doctors believed marijuana to be as effective a pain re-
liever as opium but with the added benefit of acting as an appetite 
stimulant.
28
  Marijuana was also said to “subdue restlessness and an-
xiety and distract a patient’s mind in terminal illness.”
29
  Cannabis was 
included in the United States Pharmacopoeia
30
 in 1850,
31
 and, between 
 
and until the development of synthetic fibers, it “was the most important source of 
rope.” Id. at 1.  In fact, the Declaration of Independence was drafted on hemp paper.  
See Christen D. Shepherd, Comment, Lethal Concentration of Power: How the D.E.A. Acts 
Improperly to Prohibit the Growth of Industrial Hemp, 68 UMKC L. REV. 239, 261 n.33 
(1999).  Additionally, the oil in marijuana seeds that was once “used for lighting and 
soap” is sometimes still used in the production of varnish, linoleum, and paint.  
GRINSPOON & BAKALER, supra note 21, at 1. 
 24 GRINSPOON & BAKALER, supra note 21, at 3.  The evidence was published “dur-
ing the reign of the Chinese emperor Chen Nung.”  Id.  Throughout the world, can-
nabis or hemp (including its oil) has been recommended or used to treat, inter alia, 
malaria, coughs, and urinary incontinence, “to quicken the mind, lower fevers, in-
duce sleep, cure dysentery, stimulate appetite, improve digestion, relieve headaches, 
and cure venereal disease.”  Id.  Marijuana might also be used to treat depression.  Id.   
 25 Id. at 4.  While marijuana did not “come into its own” in the West until the 
1800s, “the first definite record of the marijuana plant in the New World dates from 
1545 A.D., when Spaniards introduced it into Chile.”  GARY J. MILLER, DRUGS AND THE 
LAW: DETECTION, RECOGNITION & INVESTIGATION 405 (2nd ed. 1997).  From the early 
1600s until after the Civil War, the cannabis plant was a major crop in North America 
primarily because of its use in the production of hemp fabric.  See id. at 405–06.  
 26 GRINSPOON & BAKALER, supra note 21, at 4.  After testing cannabis on animals 
and satisfying himself that it was safe, O’Shaughnessey gave it to “patients suffering 
from rabies, rheumatism, epilepsy, and tetanus.”  Id.  O’Shaughnessy created a “tinc-
ture of hemp (a solution of cannabis in alcohol, taken orally).” Id.       
 27 Id. at 4. 
 28 Id. at 5. 
 29 Id. 
 30 The U.S. Pharmacopeia is a non-governmental, not-for-profit public-health or-
ganization that serves as “an official public standards-setting authority for all pre-
scription and over-the-counter medicines and other health care products manufac-
tured or sold in the United States.”  See About USP, U.S. PHARMECOPEIA, 
http://www.usp.org/aboutUSP/ (last visited Mar. 27, 2011).  The health organiza-
tion publishes the United States Pharmacopeia, an official compendium.  USP–NF—An 
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1840 and 1900, “more than one hundred papers were published in 
Western medical literature recommending cannabis for ‘various ill-
nesses and discomforts.’”
32
 
By 1890, physicians in the United States began reducing their re-
liance on marijuana based, in part, on the fact that “the potency of 
cannabis preparations was too variable.”
33
  Instead, physicians pre-
scribed more chemically stable and reliable synthetic drugs like aspi-
rin, chloral hydrate, and barbiturates.
34
  The advent of the hypoder-
mic needle also resulted in increased use of opiates for fast pain 
relief.
35
  Opiates, unlike hemp products, are water soluble, and, there-
fore, are easily administered by syringe.
36
  Despite its decline in use, 
medical marijuana remained legal in the United States throughout 
much of the twentieth century.  In fact, not until 1970 did Congress 
make the possession, use, or cultivation of marijuana illegal under 
federal law.
37
 
 
Overview, U.S. PHARMECOPEIA, http://www.usp.org/USPNF/ (last visited Mar. 27, 
2011).  While many sources use “pharmacopoeia,” the current accepted spelling ap-
pears to be “pharmacopeia.” 
 31 Gregg A. Bilz, The Medical Use of Marijuana: The Politics of Medicine, 13 HAMLINE 
J. PUB. L. & POL’Y 117, 118 (1992) (citing JEROME L. HIMMELSTEIN, THE STRANGE 
CAREER OF MARIHUANA 22 (1983)). Marijuana was subsequently removed from the 
U.S. Pharmacopeia in 1941.  See GRINSPOON & BAKALER, supra note 21, at 8.   
 32 GRINSPOON & BAKALER, supra note 21, at 4 (citing MARIJUANA: MEDICAL PAPERS, 
1839–1972 (T.H. Mikuriya, ed. 1973)); see also RICHARD E. ISRAELOWITZ & DARWIN 
TELIAS, DRUG USE, POLICY, AND MANAGEMENT 96 (1998)  
Among the recommended uses were as an analgesic (in the form of 
tincture of hemp—a solution of cannabis in alcohol taken orally); as a 
topical anesthetic for the mouth and tongue; and for problems and 
discomfort related to tetanus, neuralgia, dismenorrhea (painful men-
struation), convulsions, rheumatic and childbirth pain, asthma, post-
partum psychosis, gonorrhea, and chronic bronchitis, for preventing 
migraine attacks, certain kinds of epilepsy, depression, asthma, rheu-
matism, gastric ulcer, and drug addiction, particularly of morphine and 
other opiate substances. 
Id. 
 33 GRINSPOON & BAKALER, supra note 21, at 7. 
 34 Id.; see also ISRAELOWITZ & TELIAS, supra note 32, at 96.   
 35 GRINSPOON & BAKALER, supra note 21, at 7; see also ISRAELOWITZ & TELIAS, supra 
note 32, at 96.   
 36 GRINSPOON & BAKALER, supra note 21, at 7; see also ISRAELOWITZ & TELIAS, supra 
note 32, at 96.  Even with use in decline, marijuana’s medicinal properties continued 
to interest physicians, and in 1891, Dr. J.B. Mattison called cannabis “a drug that has 
a special value in some morbid conditions and the intrinsic merit and safety of which 
entitles it to a place it once held in therapeutics.”  GRINSPOON & BAKALER, supra note 
21, at 6 (citing J.B. Mattison, Cannabis Indicia as an Anodyne and Hypnotic, 61 ST. LOUIS 
MED. SURGICAL J. 266 (1891)). 
 37 See infra Part III.A. 
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B. The Controversy Behind the Science 
Over the last hundred years, public opinion in the United States 
has been divided on the medical value of marijuana.
38
  Anecdotal evi-
dence
39
 emerged in the late twentieth century suggesting that mariju-
ana has medicinal properties
40
 that provide relief from symptoms as-
sociated with numerous illnesses, including “AIDs wasting, spasticity 
from multiple sclerosis, depression, chronic pain, nausea associated 
with chemotherapy,”
41
 glaucoma,
42
 epilepsy,
43
 and migraines.
44
  Today 
there are “well-recognized therapeutic uses for cannabis, and many 
others are currently under investigation.”
45
   
 The federal government and other opponents of marijuana lega-
lization, however, have staunchly maintained a position that is re-
flected in U.S. law “that botanical marijuana is a dangerous drug 
without any legitimate medical use.”
46
  In support of their position, 
opponents emphasize that “marijuana intoxication can impair a per-
 
 38 INST. OF MEDICINE, MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE 1 (Ja-
net E. Joy et al., eds., 1999).  “Some dismiss medical marijuana as a hoax that exploits 
our natural compassion for the sick; others claim it is a uniquely soothing medicine 
that has been withheld from patients through regulations based on false claims.”  Id.   
 39 For instance, in the 1970s, people began to report that “marijuana relieved 
nausea associated with chemotherapy” and in the 1980s, “when the AIDs epidemic 
spread . . . patients found that marijuana sometimes relieved their symptoms, most 
dramatically those associated with AIDs wasting.”  Id. at 18. 
 40 Susan Corey, Recent Developments in the Therapeutic Potential of Cannabinoids, 24 P. 
R. HEALTH SCI. J. 19, 19 (2005).  
 41 See INST. OF MEDICINE, supra note 38, at 23 (stating that “patients who reported 
their experience with marijuana at the public workshops said that marijuana pro-
vided them with great relief” of symptoms associated with these illnesses).  
 42 See GRINSPOON & BAKALER, supra note 21, at 40–57. 
 43 See id. at 58–67. 
 44 See id. at 106–09.   
 45 Ruth C. Stern & J. Herbie DiFonzo, The End of the Queen’s Race: Medical Mariju-
ana in the New Century, 27 QUINNIPIAC L. REV. 673, 693 (2009).  
 46 MARK EDDY, CONG. RESEARCH SERV., RL 33211, MEDICAL MARIJUANA: REVIEW AND 
ANALYSIS OF FEDERAL AND STATE POLICIES 24 (2009) (internal citation omitted).  Ironi-
cally, “in 1978, the FDA created the Investigational New Drug (IND) Compassionate 
Access Program, allowing patients whose serious medical conditions could be re-
lieved only by marijuana to apply for and receive marijuana from the federal gov-
ernment.”  Id. at 8.  The program “was not a clinical trial to test the drug for eventual 
approval,” but it was instead a way “for the government to provide medical marijuana 
to patients demonstrating necessity.”  Id. at 8, n.32.  Over the years, less than one 
hundred patients “were admitted to the program for conditions including chemo-
therapy induced nausea and vomiting (emesis), glaucoma, spasticity, and weight 
loss,” and “in 1992, in response to a large number of applications from AIDS patients 
who sought to use medical cannabis to increase appetite and reverse wasting disease, 
the George H.W. Bush administration closed the program to all new applicants.”  Id. 
at 8.  “Several previously approved patients remain in the program today and contin-
ue to receive their monthly supply of government-grown medical marijuana.” Id.  
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son’s coordination and decision-making skills and alter behavior” and 
that “[c]hronic marijuana smoke can adversely affect the lungs, the 
cardiovascular system, and possibly the immune and reproductive sys-
tems.”
47
 
C. The Science Behind the Controversy: The Benefits of Botanical 
Medical Marijuana Often Outweigh the Risks 
Underlying much of the controversy is the fact that proponents 
of medical marijuana seek to legalize use of the actual plant rather 
than a synthetic version of its primary chemical, tetrahydrocannabi-
nol (THC).  Marijuana generally “refers to the dried flowers, leaves, 
stems and seeds of the Cannabis sativa plant.”
48
  It contains over 460 
known compounds,
49
 including at least sixty chemicals known as can-
nabinoids.
50
  Among these are delta-9 THC, the primary psychoactive 
component in marijuana, and cannabigerol, cannabinol, and canna-
bidiol—non-psychoactive cannabinoids.
51
  While THC is the primary 
psychoactive component of marijuana, not all of the effects of mari-
juana on the human body are the result of THC.
52
 
Studies show that “cannabinoids produce most of their effect” by 
binding to receptors on the surface of certain types of cells, each of 
which only recognizes “a few specific molecules, known collectively as 
ligands.”
53
  “When the appropriate ligand binds to its receptor, it typi-
cally sets off a chain of biochemical reactions inside the cell.”
54
  The 
receptors that bind cannabinoids are “cannabinoid receptors.”
55
  To 
date, researchers have discovered two types of cannabinoid receptors: 
CB1 and CB2.
56
  CB1 “mediates the central nervous system,” and CB2 
 
 47 Id. at 24 (citing Exposing the Myth of Medical Marijuana, DEP’T OF JUSTICE, DRUG 
ENFORCEMENT AGENCY, http://www.justice.gov/dea/ongoing/marijuanap.html (last 
visited Feb. 19, 2010)). 
 48 Marijuana as Medicine: Consider the Pros and Cons, MAYO CLINIC (Oct. 27, 2009), 
http://www.riversideonline.com/health_ reference/Articles/GA00014.cfm.  
 49 GRINSPOON & BAKALER, supra note 21, at 2. 
 50 MAYO CLINIC, supra note 48.  
 51 See id.; see also ALLISON MACK & JANET JOY, MARIJUANA AS MEDICINE? THE SCIENCE 
BEYOND THE CONTROVERSY 27 (2001). 
 52 MACK & JOY, supra note 51, at 8 (“[A] complex mixture of chemical compounds 
[exists in the marijuana plant and] . . . . the effects of marijuana on the body include 
those of THC . . . not all of marijuana’s effects are necessarily due to THC alone.”).   
 53 Id. at 27. 
 54 Id. 
 55 Id. at 28. 
 56 AM. COLL. OF PHYSICIANS, POSITION PAPER: SUPPORTING RESEARCH INTO THE 
THERAPEUTIC ROLE OF MARIJUANA 4 (2008), available at 
http://www.csdp.org/research/medmarijuana.pdf. 
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“occurs outside the [central nervous system] and is believed to have 
anti-inflammatory and immunosuppressive activity.”
57
 
In 1985, the Food and Drug Administration (FDA) approved 
Marinol (Dronabinol), a synthetic form of THC encapsulated in se-
same oil,
58
 to treat “nausea and vomiting associated with cancer che-
motherapy patients who fail to respond to conventional antiemetic 
treatments.”
59
  The FDA later approved Marinol “for the treatment of 
anorexia associated with weight loss in patients with AIDs.”
60
  Al-
though Marinol was originally a Schedule II drug, the DEA moved it 
to Schedule III in 1999 after it and the “Department of Health and 
Human Services found little evidence of illicit abuse of the drug.”
61
  
In 2006, the FDA approved Cesamet (Nabilone), another synthetic 
cannabinoid similar to THC, for the treatment of chemotherapy-
induced nausea and vomiting.
62
  Cesamet is a Schedule II drug.
63
  In 
2005, Canada approved Sativex, “a whole plant extract that contains 
THC and cannabidiol,”
64
 for use in treating neuropathic pain asso-
ciated with multiple sclerosis (MS).
65
  Canada also approved the oral 
spray, which is absorbed in the patient’s mouth, as “adjunctive anal-
gesic treatment in patients with advanced cancer who experience 
moderate to severe pain during the highest tolerated dose of strong 
opioid therapy” in 2007.
66
  It is currently in clinical trials, being stu-
died for the treatment of patients with advanced cancer whose pain is 
not being relieved by strong opioid medications.
67
 
The FDA’s approval of synthetic cannabinoid-based medications 
evidences that marijuana’s components have therapeutic properties.  
But for a subset of patients, the natural plant is superior because 
smoking may actually be a preferred drug-delivery system.  Oral THC 
 
 57 Id. 
 58 INST. OF MEDICINE, supra note 38, at 202. 
 59 EDDY, supra note 46, at 8. 
 60 Id.     
 61 Id.  In contrast, marijuana in its natural form is a Schedule I drug.  See infra 
Part III.A for a discussion about the scheduling of drugs under federal law. 
 62 Valeant Receives FDA Marketing Approval for Cannabinoid Cesamet, DRUGS.COM (May 
16, 2006), http://www.drugs.com/ news/valeant-receives-fda-marketing-approval-
cannabinoid-cesamet-1794.html.   
 63 Cesamet, RXLIST.COM, http://rxlist.com/cesamet-drug.htm (last visited Mar. 31, 
2010). 
 64 Wendy Koch, Spray Alternative to Pot on the Market in Canada, USA TODAY, June 
24, 2005, at 4A. 
 65 Sativex, GW PHARMS., http://gwpharm.com/sativex.asp (last visited Jan. 4, 
2010). 
 66 Id. 
 67 Id.  
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is slower to take effect than smoked marijuana and “produces more 
pronounced, and often unfavorable, psychoactive effects that last 
much longer than those experienced with smoking.”
68
  In contrast, 
“smoked THC is quickly absorbed into the blood and effects are ex-
perienced immediately.”
69
  The fast-acting nature of smoked marijua-
na also “allows patients to easily determine the right dose for symp-
tom relief.”
70
  With oral cannabinoid medications, patients cannot 
similarly “self-titrate”
71
 because “absorption is highly variable and un-
predictable and often delayed” when THC is taken orally.
72
  For pa-
tients whose severe nausea and vomiting prevent them from taking 
anything orally, such as those undergoing cancer chemotherapy, in-
halation is the only alternative.
73
  Additionally, some doubt that syn-
thetics are sufficient substitutes: “[S]ingle-cannabinoid, synthetic 
pharmaceuticals like Marinol are poor substitutes for the whole mari-
juana plant, which contains more than 400 known chemical com-
pounds, including about 60 active cannabanoids in addition to 
THC.”
74
  Finally, natural marijuana is cheaper and easier to manufac-
ture than synthetic cannabioid-based medications, which are expen-
sive.
75
 
Modern medical evidence supports using marijuana to treat the 
symptoms of a range of debilitating illnesses, including pain, loss of 
appetite, nausea, and spasticity.
76
  While some FDA-approved medica-
tions are arguably “more effective” than marijuana, some people may 
not respond well to other medicine—they may not experience relief 
 
 68 AM. COLL. OF PHYSICIANS, supra note 56, at 7 (citing J. Beal et al., Long-Term Effi-
cacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-Associate Anorexia, 
14(1) J. OF PAIN AND SYMPTOM MGMT. 7–14 (1997)). 
 69 Id. 
 70 Lester Grinspoon, Puffing is the Best Medicine, L.A. TIMES, May 5, 2006, at B13. 
 71 See id.  
 72 Jill U. Adams, A Balm for Pain, L.A. TIMES, Aug. 18, 2008, at F6 (quoting Dr. 
Igor Grant, a University of California, San Diego psychiatrist who directs the universi-
ty’s Center for Medicinal Cannabis Research).   
 73 See EDDY, supra note 46, at 29. 
 74 Id. at 26.  In addition to the fact that “many patients have found that they ben-
efit more from the whole plant than from any synthetically produced chemical deriv-
ative,” proponents argue that “scientists are a long way from knowing for sure which 
ones, singly or in combination, provide which therapeutic effects.”  Id. (internal cita-
tion omitted). 
 75 Id. at 26–27 (noting that Marinol currently retails for approximately $17 per 
pill).  
 76 See  AM. COLL. OF PHYSICIANS, supra note 56, at 3–6. 
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or may be unable to tolerate the side effects—or may simply respond 
better to marijuana.
77
 
In short, the natural form of marijuana may be preferable for a 
small subset of patients for whom current products are ineffective, or 
at least less effective, than marijuana.  For example, many cancer pa-
tients suffer from “profound nausea and vomiting” as a side effect of 
chemotherapy.
78
  The cannabinoids in marijuana are an effective 
treatment for this debilitating adverse effect, which the FDA approval 
of Marinol and Cesamet evidences.  Additionally, a review of thirty 
clinical studies published in the European Journal of Cancer Care re-
ported that cannabinoid drugs have an anti-emetic efficacy superior 
to conventional anti-nausea drugs.
79
 
In AIDS and HIV patients, marijuana relieves a number of symp-
toms, including wasting (cachexia)
80
 and pain.  It can also improve 
 
 77 INST. OF MEDICINE, supra note 38, at 3–4.  
 78 GRINSPOON & BAKALER, supra note 21, at 25.   
Retching (dry heaves) may last for hours or even days after each treat-
ment, followed by days and even weeks of nausea.  Patients may break 
bones or rupture the esophagus while vomiting. The sense of a loss of 
control can be emotionally devastating.  Furthermore, many patients 
eat almost nothing because they cannot stand the sight or smell of 
food.  As they lose weight and strength, they find it more and more dif-
ficult to sustain the will to live.   
Id.  “For many patients, the side effects of chemotherapy seem worse than the cancer 
itself, and they discontinue treatment, not only to eliminate the discomfort but also 
to regain control over their lives.” Id.  
 79 F.C. Machado Rocha et al., Therapeutic Use of Cannabis Sativa on Chemotherapy-
Induced Nausea and Vomiting Among Cancer Patients: Systematic Review and Meta-Analysis, 
17 EUR. J. OF CANCER CARE 431, 440 (2008), available at 
http://www.phillynorml.org/documents/legis_files/08_Review%20Cannabis%20sati
va%20chemotherapy%20enemia_Rocha_EJCC.pdf; see also Martin R. Tramèr et al., 
Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Sys-
tematic Review, 323 BRIT. MED. J. 16, 20 (2001) (finding cannabinoids to be superior to 
conventional antiemetics after chemotherapy, that patients preferred them, and that 
“[i]n selected patients, cannabinoids may be useful as mood enhancing adjuvants for 
the control of chemotherapy related sickness”).  The study authors stated that “po-
tentially serious adverse effects . . . are likely to limit their widespread use,” but also 
noted that “some side effects could be classified as potentially beneficial (for in-
stance, a sensation of a ‘high,’ euphoria, and drowsiness, sedation, or somnolence).”  
Id. at 18, 20. 
 80 “Wasting syndrome in acquired immune deficiency syndrome (AIDS) patients 
is defined by the Centers for Disease Control and Prevention as the involuntary loss 
of more than 10% of baseline average body weight in the presence of diarrhea or 
fever of more than 30 days that is not attributable to other disease processes.”  INST. 
OF MEDICINE, supra note 38, at 154 (internal citation omitted).   
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mood and sleep.
81
  The FDA’s approval of Marinol for the treatment 
of “anorexia associated with weight loss in patients with AIDS” evi-
dences the fact that marijuana and its cannabinoids can stimulate the 
appetite.
82
  Additionally, according to the American College of Physi-
cians, “research supporting THC as an effective appetite stimulant 
and antiemetic is abundant,” and “[c]linical trials have demonstrated 
that both oral and smoked marijuana stimulate appetite, increase ca-
loric intake, and result in weight gain among patients experiencing 
HIV wasting.”
83
  One double-blind study published in the Journal of 
Acquired Immune Deficiency Syndromes compared the effects of Marinol 
and marijuana on cognitive performance, mood, appetite stimula-
tion, and sleep in HIV-positive marijuana smokers.
84
  It found that 
Marinol and marijuana both “produced substantial and comparable 
increases in food intake” and “improved mood without producing 
disruptions in psychomotor functioning,” but that “[smoked] mariju-
ana has the added benefit of improving sleep ratings.”
85
  The study al-
so noted that ninety-three percent of the patients surveyed preferred 
smoked marijuana to Marinol.
86
  Finally, “neither marijuana nor [Ma-
rinol] significantly altered performance on any of the tasks (e.g., 
measures of learning, memory, vigilance, psychomotor ability),” and 
the researchers stated that the “present data indirectly suggest that 
tolerance selectively develops to the cognitive effects of marijuana 
and [Marinol].”
87
 
Researchers have also found that smoked marijuana is well-
tolerated and effective in treating neuropathic pain in patients with 
HIV-associated sensory neuropathy.
88
  Although anticonvulsants can 
also be effective, “some patients fail to respond or cannot tolerate” 
them.
89
 
Marijuana is also effective in the treatment of symptoms of MS.  
“[P]ainful muscle spasms are among the most common and distress-
 
 81 See Margaret Haney et al., Dronabinol and Marijuana in HIV-Positive Marijuana 
Smokers: Caloric Intake Mood and Sleep, 45 J. ACQUIR. IMMUNE DEFIC. SYNDR. 545, 552 
(2007).   
 82 See EDDY, supra note 46, at 8. 
 83 AM. COLL. OF PHYSICIANS, supra note 56, at 4 (internal citation omitted).  
 84 Haney et al., supra note 81, at 545.   
 85 Id. at 552.  
 86 Id.  
 87 Id. at 550–52. 
 88 Donald I. Abrams et al., Cannabis in Painful HIV-Associated Sensory Neuropathy: A 
Randomized Placebo-Controlled Trial, 68 NEUROLOGY 515, 515 (2007).  HIV-associated 
sensory neuropathy is a painful nerve disorder.  See id.  
 89 Id. (internal citation omitted).  
BROWN_FINAL.DOC (DO NOT DELETE) 11/22/2011  9:06 AM 
2011] COMMENT 1531 
ing symptoms,” severely influencing patients’ quality of life.
90
  Current 
therapeutic options are often expensive or unavailable.
91
  Most impor-
tantly,  these drugs do not wholly ameliorate quality of life issues—
“available oral anti-spasticity medications often only give partial relief 
and have gastrointestinal or psychotropic side effects.”
92
  According to 
researchers, “[a]necdotal evidence, preclinical data, small clinical re-
ports, and phase 2 trials, suggest that cannabis derivatives may play a 
useful role in alleviating muscle spasms, tremors, pain, and bladder 
dysfunction associated with MS.”
93
  In 2005, a “randomized, double-
blind, placebo-controlled cross-over study of an orally administered 
standardized Cannabis sativa plant extract in patients with MS-
induced spasticity . . . found the extract to be safe and well tolerated 
and that it may reduce spasm frequency” and increase mobility.
94
  The 
study also noted that “beneficial effects upon sleep” were consistent 
with other studies.
95
  In another study, researchers found smoked ma-
rijuana to be “superior to placebo in reducing spasticity and pain.”
96
  
Additionally, while the National Multiple Sclerosis Society has not yet 
recommended that medical marijuana be made widely available to 
people with MS, it has stated that “it is clear that cannabinoids have 
potential both for the management of MS symptoms such as pain and 
spasticity, as well as for neuro-protection.”
97
 
Marijuana and its constituent cannabinoids are not completely 
without their side effects, which include diminished psychomotor 
performance, unpleasant feelings, and “short term immunosuppres-
 
 90 C. Vaney et al., Efficacy, Safety, and Tolerability of an Orally Administered Cannabis 
Extract in the Treatment of Spasticity in Patients with Multiple Sclerosis: A Randomized, 
Double-Blind, Placebo-Controlled, Crossover Study, 10 MULTIPLE SCLEROSIS 417, 417 (2004) 
(citing L. Provinciali et al., A Multidimensional Assessment of Multiple Sclerosis: Relation-
ship Between Disability Domains, 100 ACTA NEUROL SCAND 156–62 (1999)).  
 91 Id. 
 92 Id.  
 93 Id. (internal citation omitted). 
 94 Id. at 421, 423. 
 95 Id. at 422. 
 96 Jody Corey-Bloom et al., Short-Term Effects of Medicinal Cannabis on Spasticity in 
Multiple Sclerosis, http://cmcr.ucsd.edu/images/pdfs/Corey-Bloom_poster_1.pdf 
(last visited May 28, 2011).  Study investigators noted, however, that “although gen-
erally well tolerated” smoked cannabis “resulted in statistically significant cognitive 
effects.”  Id.  
 97 NAT’L MULTIPLE SCLEROSIS SOCIETY, EXPERT OPINION PAPER: RECOMMENDATIONS 
REGARDING THE USE OF CANNABIS IN MULTIPLE SCLEROSIS (2008), available at 
http://www.nationalmssociety.org/for-professionals/healthcare-
professionals/publications/expert-opinion-papers/index.aspx. 
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sive effects.”
98
  But no “case of human death by cannabis poisoning” 
has ever been published.
99
  Some have even stated that “[m]arihuana 
in its natural form is possibly the safest therapeutically active sub-
stance known to humanity.”
100
  According to the Institute of Medi-
cine, “except for the harms associated with smoking, the adverse ef-
fects of marijuana use are within the range of effects tolerated for 
other medications.”
101
 
Despite conflicting evidence, some have argued that marijuana 
smoking causes cancer.  In fact, “[l]ong term exposure to cannabis 
smoke has long been thought to increase the risk of respiratory can-
cers as well as cancers of the mouth, tongue, and esophagus.”
102
  Mari-
juana smoke does contain “many of the components of tobacco 
smoke,” and far more tar “can be deposited in the lungs” of a mariju-
ana smoker than that of a cigarette smoker with cigarettes of compa-
rable weight.
103
  This is due primarily to the fact that “[m]arijuana 
cigarettes usually do not have filters, and marijuana smokers typically 
develop a larger puff volume, inhale more deeply, and hold their 
breath several times longer than tobacco smokers.”
104
 
But in a study funded by the National Institute of Health’s Na-
tional Institute on Drug Abuse, Dr. Donald Tashkin, a pulmonologist 
at the University of California at Los Angeles, found that “[p]eople 
who smoke marijuana—even heavy, long-term marijuana users—do 
not appear to be at an increased risk of developing lung cancer”
105
 or 
other head and neck cancers, including cancer of the tongue, mouth, 
throat or esophagus.
106
  The heaviest smokers that participated in the 
 
 98 INST. OF MEDICINE, supra note 38, at 5.  The authors note that “the short term 
immunosuppressive effects are not well established, but if they exist, they are not 
likely great enough to preclude a legitimate medical use.”  Id.  
 99 Stern & DiFonzo, supra note 45, at 700 (citing Wayne Hall & Nadia Solowij, 
Adverse Effects of Cannabis, 352 LANCET 1611, 1612 (1998)).   
 100 GRINSPOON & BAKALER, supra note 21, at 138. 
 101 INST. OF MEDICINE, supra note 38, at 5. 
 102 Stern & DiFonzo, supra note 45, at 701 (citing Wayne Hall et al., Cannabinoids 
and Cancer: Causation, Remediation, and Palliation, 6 LANCET ONCOLOGY 35, 37 (2005)).   
 103 INST. OF MEDICINE, supra note 38, at 111 (internal citations omitted).  
 104 Id. (citation omitted).  
 105 Press Release, Am. Thoracic Soc’y, Study Finds No Link Between Marijuana 
Use and Lung Cancer (May 23, 2006), available at 
http://www.thoracic.org/sections/publications/press-
releases/conference/articles/2006/press-releases/study-finds-no-link-between-
marijuana-use-and-lung-cancer.html).  These findings were presented at the Ameri-
can Thoracic Society International Conference on May 23, 2006.  Id. 
 106 Marc Kaufman, Study Finds No Cancer-Marijuana Connection, WASH. POST, May 
26, 2006, at A3; Am. Thoracic Soc’y, supra note 105; see also Tashkin DP et al., Mariju-
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study had smoked more than twenty-two-thousand marijuana ciga-
rettes in their lives,
107
 an amount Dr. Tashkin described as “enorm-
ous.”
108
  The results surprised Dr. Tashkin, who has studied marijuana 
for more than thirty years, because “previous studies found that mari-
juana tar has 50 percent higher concentrations of chemicals linked to 
cancer than tobacco cigarette tar” and because “marijuana users in-
hale more deeply and generally hold smoke in their lungs longer 
than tobacco smokers, exposing them to dangerous chemicals for a 
longer time.”
109
  According to Dr. Tashkin, a possible explanation for 
the finding is that “THC . . . may encourage aging cells to die earlier 
and therefore be less likely to undergo cancerous transformation.”
110
  
Ironically, “[f]ederal health and drug enforcement officials have 
widely used Tashkin’s previous work on marijuana to make the case 
that the drug is dangerous.”
111
 
Other studies have, however, found an increased cancer risk as-
sociated with smoking marijuana.  A systematic review of “studies as-
sessing the impact of marijuana smoking on lung premalignant find-
ings and lung cancer” concluded the same year as the Tashkin study 
stated that 
[g]iven the prevalence of marijuana smoking and studies predo-
minantly supporting biological plausibility of an association of 
marijuana smoking and lung cancer on the basis of molecular, 
cellular, and histopathologic findings, physicians should advise 
patients regarding potential adverse health outcomes until fur-
 
ana Use and Lung Cancer: Results of a Case-Control Study, UKCIA, May 24, 2006, 
http://www.ukcia.org/research/MjUseAndLungCancer.php. 
 107 Am. Thoracic Soc’y, supra note 105.   
 108 Neil Osterweill, ATS: Marijuana Smoking Found Non-Carcinogenic, MEDPAGE 
TODAY (May 24, 2006) 
http://www.medpagetoday.com/HematologyOncology/LungCancer/3393. 
 109 Kaufman, supra note 106. 
 110 Am. Thoracic Soc’y, supra note 105.  Further, in regard to the effect of mariju-
ana smoking on lung health, according to Dr. Tashkin, “we can be close to conclud-
ing that smoking marijuana by itself does not lead to [chronic obstructive pulmonary 
disease].”  Donald P. Tashkin, Does Smoking Marijuana Increase the Risk of Chronic Ob-
structive Pulmonary Disease?, 180 CANADIAN MED. ASSOC. J. 797, 798 (2009).  “COPD 
(chronic obstructive pulmonary disease) is a serious lung disease which makes it hard 
to breathe.  Also known by other names, such as emphysema or chronic bronchitis, 
COPD is now the 4th leading cause of death in the United States and also causes 
long-term disability.”  Chronic Obstructive Pulmonary Disease, NAT’L HEART LUNG AND 
BLOOD INST., http://www.nhlbi.nih.gov/health/public/lung/copd/ (last visited Mar. 
27, 2011). 
 111 Kaufman, supra note 106. 
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ther rigorous studies are performed that permit definitive conclu-
sions.
112
 
Another study published in the European Respiratory Journal in 2008 
reportedly found a fivefold increase in risk of lung cancer in individ-
uals who smoked marijuana daily for ten years but “no effect in less 
heavy users.”
113
  Responding to these study results, Dr. Tashkin attri-
buted what he referred to as the “vastly inflated estimates” to the 
small sample size.
114
 
More clinical research is needed to establish definitively whether 
the medical use of marijuana is detrimental to the lungs or leads to 
an increase in lung cancer.  Unquestionably, however, for some ter-
minally ill patients, the immediate benefits of medical marijuana 
outweigh the risk of potentially developing lung cancer.
115
  Even if 
smoking cannabis does affect lung health, patients can lessen the risk 
of harm by using a vaporizer, which heats marijuana enough to re-
lease the cannabinoids without combustion and the “attendant 
smoke toxins.”
116
  In fact, researchers have found that “vaporization of 
cannabis is a safe and effective mode of delivery of THC.”
117
  Patients 
can also cook and eat marijuana in its botanical form.
118
 
Opponents of the medical use of marijuana have also pointed to 
the effect of marijuana on the immune system, which could be par-
ticularly dangerous to patients with compromised immune systems, 
such as those living with AIDS or cancer.  But the “effect is difficult to 
understand because studies are contradictory.”
119
  Some studies have 
shown that “marijuana weakens the immune system”
120
 while others 
have found that “cannabis stimulates the immune system and plays an 
 
 112 Reena Mehra et al., A Systematic Review: The Association Between Marijuana Smok-
ing and Lung Cancer, 166 ARCH. INTERN. MED. 1359, 1367 (2006). 
 113 Jill U. Adams, Damaging Habit?, L.A. TIMES, Aug 18, 2008, at F6. 
 114 Id. 
 115 See INST. OF MEDICINE, supra note 38, at 159 (“Terminal cancer patients pose 
different issues.  For those patients the medical harms associated with smoking is of 
little consequence.  For terminal patients suffering debilitating pain or nausea and 
for whom all indicated medications have failed to provide relief, the medical benefits 
of smoked marijuana might outweigh the harm.”). 
 116 D.I. Abrams et al., Vaporization as a Smokeless Cannabis Delivery System: A Pilot 
Study, 82 CLINICAL PHARMACOLOGY & THERAPEUTICS 571, 571 (2007). 
 117 Id.  
 118 See EDDY, supra note 46, at 29. 
 119 Stern & DiFonzo, supra note 45, at 701–02. 
 120 See Exposing the Myth of Medical Marijuana, supra note 47 (citing I. B. Adams et 
al., Cannabis: Pharmacology and Toxicology in Animals and Humans, 91 ADDICTION 1585, 
1585–1614 (1996)). 
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important role in controlling immune responses.”
121
  Some have criti-
cized the studies that have shown immune suppression as misleading 
because of the “very high concentrations of drug used to produce” 
the results.
122
  Ultimately, no conclusive determination can be made 
as to marijuana’s impact on the immune system. 
Opponents and public policy makers involved in the “war on 
drugs” continue to hold that marijuana is a “gateway” drug because 
“most users of other illicit drugs have used marijuana first.”
123
  But 
“there is no conclusive evidence that the drug effects of marijuana 
are causally linked to the subsequent abuse of other illicit drugs.”
124
  
Furthermore, the Institute of Medicine has noted that any evidence 
supporting the “gateway” theory is inapplicable to medical marijuana 
and that whether “medical availability would increase drug abuse” is 
“beyond the issues normally considered for medical use of drugs and 
should not be a factor in evaluating the therapeutic potential of mari-
juana or cannabinoids.”
125
 
Data from states with medical-marijuana laws have also consis-
tently shown that legalization of medical marijuana does not send the 
wrong message to children or increase recreational use of the drug.
126
  
According to a study by the Marijuana Policy Project advocacy organi-
zation, “data shows that no state with a medical marijuana law has ex-
perienced an increase in youth marijuana use since their law’s 
enactment,” and “all states have reported overall decreases—
exceeding 50% in some age groups.”
127
  Additionally, legalizing the 
medical use of marijuana does not decriminalize recreational use of 
the drug; people who use marijuana for recreational purposes are 
still subject to federal and state criminal penalties. 
 
 121 Stern & DiFonzo, supra note 45, at 702 (citing J. Ludovic Croxford et al., Can-
nabinoids and the Immune System: Potential for the Treatment of Inflammatory Disease?, 166 
J. NEUROIMMUNOLOGY 3, 4 (2005)).  Additionally, in one study, “oral or smoked can-
nabinoids did not prove unsafe to patients infected with HIV.”  Id.  (citing Oliver Ul-
rich et al., Immune Control by Endocannabinoids—New Mechanisms of Neuroprotection?, 
184 J. NEUROIMMUNOLOGY 127, 129 (2006)). 
 122 See Leo E. Hollister, Marijuana and Immunity, 24 J. OF PSYCHOACTIVE DRUGS 
159,159–63 (1992). 
 123 INST. OF MEDICINE, supra note 38, at 6 (“[M]ost users of other illicit drugs have 
used marijuana first.”). 
 124 Id. 
 125 Id. at 7.  
 126 See KAREN O’KEEFE ET AL., MARIJUANA POLICY PROJECT, MARIJUANA USE BY YOUNG 
PEOPLE: THE IMPACT OF STATE MEDICAL MARIJUANA LAW (2008), available at 
http://www.phillynorml.org/documents/legis_files/TeenUseReport_0608.pdf. 
 127 Id. at 1. 
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A large number of organizations “support the use of marijuana 
as a medicine,”
128
 and many more support medical-marijuana re-
search,
129
 including the Institute of Medicine and the American Col-
lege of Physicians (ACP).
130
  The ACP also advocates reviewing mari-
juana’s Schedule I classification and protecting patients using 
marijuana in compliance with state law from federal criminal prose-
cution.
131
 
The bottom line is that marijuana and its constituent cannabino-
ids can be superior to available alternatives for symptom relief in cer-
tain patient populations.  While there are health risks associated with 
smoking marijuana, the benefits appear to outweigh the harms for 
some patients with debilitating medical conditions, such as the ter-
minally ill.  As the Leukemia and Lymphoma Society has stated, “[I]t 
cannot seriously be contested that there exists a small but significant 
class of individuals who suffer from painful chronic, degenerative, 
and terminal conditions, for whom marijuana provides uniquely ef-
fective relief.”
132
  Citizens of New Jersey will now have access to that 
relief. 
III. LEGAL BACKGROUND 
A. Federal Prohibition of Marijuana Under the Controlled  
Substances Act 
The possession, distribution, or cultivation of marijuana, even 
for medical purposes, violates the federal Controlled Substance Act 
(CSA) and Title II of the Comprehensive Drug Abuse Prevention and 
 
 128 See Health Organizations’ Endorsements, NAT’L ORG. FOR THE REFORM OF 
MARIJUANA LAWS (NORML), http://norml.org/index.cfm?Group_ID=3388 (last up-
dated June 17, 2004).  These organizations include the American Academy of Family 
Physicians, AIDS Action Council, the American Medical Student Association, the 
American Nurses Association, the American Preventive Medical Association, the 
American Public Health Association, the National Association for Public Health Poli-
cy, the New England Journal of Medicine, and the New Jersey State Nurses Associa-
tion.  Quick Reference, NAT’L ORG. FOR THE REFORM OF MARIJUANA LAWS (NORML), 
http://norml.org/index.cfm?Group_ID=3389 (last updated June 16, 2008).  
 129 Id.  This includes the American Cancer Society.  Id.  
 130 See INST. OF MEDICINE, supra note 38, at 10–11; AM. COLL. OF PHYSICIANS, supra 
note 56, at 3. 
 131  AM. COLL. OF PHYSICIANS, supra note 56, at 3.  
 132 EDDY, supra note 46, at 26 (citing Brief for the Leukemia and Lymphoma Socie-
ty et al. as Amici Curiae Supporting Respondents at 4, Gonzales v. Raich, 545 U.S. 1 
(2005) (No. 03-1454)).  
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Control Act of 1970.
133
  In fact, the CSA applies even to entirely intras-
tate marijuana-related activities.
134
  Under the CSA, controlled sub-
stances are categorized into five schedules “based on their accepted 
medical uses, the potential for abuse, and their psychological and 
physical effects on the body.”
135
  Marijuana is classified as a Schedule I 
controlled substance.
136
  Schedule I drugs are those considered to 
have “a high potential for abuse,” to lack “currently accepted medical 
use in treatment,” and to lack accepted safety for use under medical 
supervision.
137
  “By classifying marijuana as a Schedule I drug, as op-
posed to listing it on a lesser schedule, the manufacture, distribution, 
or possession of marijuana became a criminal offense, with the sole 
exception being use of the drug as part of a Food and Drug Adminis-
tration pre-approved research study.”
138
  Additionally, as a Schedule I 
drug, physicians may not prescribe and pharmacists are precluded 
from dispensing marijuana.
139
  Simple possession of marijuana for 
personal use is a misdemeanor under federal law
140
 that carries a sen-
 
 133 21 U.S.C. § 841(a)(1) (2006) (making it unlawful to knowingly or intentionally 
“manufacture, distribute, or dispense, or possess with intent to manufacture, distri-
bute, or dispense, a controlled substance” except as authorized by this title);  id. § 
844(a) (making it unlawful to knowingly or intentionally possess a controlled sub-
stance); id. § 812 Schedule I (c)(10) (classifying marijuana as a Schedule I controlled 
substance). 
 134 Congress is authorized to enact laws regulating interstate commerce under the 
Commerce Clause of the United States Constitution.  See U.S. CONST. art. 1, § 8, cl. 3.  
Congress exercised its Commerce Clause power when it enacted the CSA.  See Tam-
my L. McCabe, Comment, It’s High Time: California Attempts to Clear the Smoke Sur-
rounding the Compassionate Use Act, 35 MCGEORGE L. REV. 545, 547 (2004) (finding that 
local cultivation and distribution of controlled substances not integral to the flow of 
interstate commerce nonetheless have a “substantial and direct effect” on interstate 
commerce and contribute to the swelling of interstate traffic of controlled substances 
(citing 21 U.S.C.A. § 801(3)–(6) (West 1999))).  The CSA applies to entirely “intras-
tate marijuana-related activities, including cultivation, possession, transportation and 
distribution of marijuana” in any state.  See id.; see also Gonzales v. Raich, 545 U.S. 1, 9 
(2005) (“Congress’ Commerce Clause authority includes the power to prohibit the 
local cultivation and use of marijuana in compliance with California law.”).  
 135 Gonzales, 545 U.S. at 13 (citing 21 U.S.C. §§ 811, 812 (2000)); see also 21 U.S.C. 
§ 812 (2006) (listing the criteria for each schedule).  
 136 § 812 Schedule I(c)(10).  
 137 § 812(b)(1).  In contrast, drugs with recognized medical uses, such as opium, 
cocaine, and amphetamine, were assigned to Schedules II through V, depending on 
their potential for abuse.  EDDY, supra note 46, at 3 (citation omitted); see also § 812. 
 138 Gonzales, 545 U.S. at 14 (citing 21 U.S.C. §§ 823(f), 841(a)(1), 844(a) (2000); 
United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 490 (2001)).    
 139 See 21 U.S.C. § 829 (2006) (detailing how drugs classified in Schedules II 
through V may be prescribed and dispensed); see also Oakland Cannabis Buyers’ Coop., 
532 U.S. at 491–92.  
 140 See H.R. REP. NO. 91-1444 (1970), reprinted in 1970 U.S.C.C.A.N. 4566, 4570–77. 
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tence of up to one year in federal prison and a maximum fine of 
$100,000 for a first offense.
141
  Furthermore, the cultivation of mariju-
ana is a felony under federal law;
142
 the growth of just one plant car-
ries up to five years in federal prison and a fine of up to $250,000 for 
a first offense.
143
  Despite the widespread recognition of the potential 
therapeutic benefits of marijuana,
144
 repeated attempts to remove ma-
rijuana from the CSA or have it re-scheduled on the federal level
145
 
have failed.
146
 
B. The States Take Action: A Brief Overview of State Medical-
Marijuana Laws 
Medical-marijuana advocates have had greater success with lega-
lization at the state level.  Between 1978 and 2008, thirty-six states and 
the District of Columbia enacted some type of medical-marijuana 
 
 141 See 21 U.S.C. § 844(a) (2006); 18 U.S.C. § 3571(b)(5) (2006).  
 142 See 21 U.S.C. § 802(15) (2006) (defining “manufacture” to include “produc-
tion” of a drug); § 802(22) (defining “production” to include, inter alia, cultivation or 
growing of a controlled substance); see also United States v. Angel, 576 F.3d 318, 321 
n.2 (6th Cir. 2009) (“The manufacture or cultivation of marijuana is a felony offense 
under . . . federal . . . law.” (citing § 841(a)(1), (b)(1)(D)(1))).  
 143 Id. § 841(b)(1)(D).   
 144 See supra Part II. 
 145 The CSA authorizes the Attorney General to determine appropriate schedul-
ing of controlled substances and to transfer substances between schedules if it finds 
that a drug does not meet the criteria for an individual schedule.  See 21 U.S.C.  § 811 
(2006).  The Attorney General has delegated this authority to the Administrator of 
the Drug Enforcement Administration.  28 C.F.R. § 0.100(b) (2006).  Additionally,  
[b]ecause Congress created the Controlled Substances Act (CSA), 
Congress can change it.  Some possibilities include: passing a bill to 
move marijuana into a less restrictive schedule; moving marijuana out 
of the CSA entirely; or even replacing the entire CSA with something 
completely different.  In addition, Congress can remove criminal pe-
nalties for the medical use of marijuana regardless of what schedule it 
is in.  
MARIJUANA POLICY PROJECT, supra note 10, at 4.  Finally, “[b]ecause the F[ood] [and] 
D[rug] A[dministration] is part of the U.S. Department of Health and Human Ser-
vices (HHS), the U.S. Secretary of Health and Human Services can declare that mari-
juana meets sufficient standards of safety and efficacy to warrant rescheduling.”  Id.   
 146 See Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1131, 1137 (D.C. 
Cir. 1994) (noting that petitions to reschedule marijuana were first filed in 1972 and 
had been before the U.S. Court of Appeals for the District of Columbia Circuit on 
four prior occasions and upholding the Administrator of the Drug Enforcement 
Administration’s denial to reschedule marijuana); Drug Enforcement Administra-
tion, Notice of Denial of Petition, 66 Fed. Reg. 20,038 (2001) (denying a petition to 
reschedule marijuana based on the scientific and medical findings of the Depart-
ment of Health and Human Services that marijuana has a high potential for abuse); 
see also Gettman v. DEA, 290 F.3d 430 (D.C. Cir. 2002); Krumm v. Holder, No. CIV 
08-1056 JB/WDS, 2009 U.S. Dist. LEXIS 52748 (D.N.M. May 27, 2009).  
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law;
147
 currently, laws in thirty-one states and the District of Columbia 
“recognize marijuana’s medicinal value.”
148
  Unfortunately, federal re-
strictions render many of these state laws ineffective and merely sym-
bolic.
149
  For instance, a number of state laws allow possession of mari-
juana obtained by a physician’s prescription.
150
  Several other states 
and the District of Columbia have re-scheduled marijuana at the state 
level to recognize the drug’s therapeutic value.
151
  These laws do little 
to provide individuals with legal access to medical marijuana, howev-
er, because physicians are still unable to prescribe and pharmacists 
are still unable to dispense marijuana without violating federal law.
152
  
Seven states have also passed “non-binding resolutions urging the 
federal government to make marijuana medically available.”
153
  While 
these resolutions carry little legal weight, they clearly symbolize that 
the states recognize the need to provide individuals with access to a 
medication that has palliative effects. 
In 1996, California was the first state in the nation to pass an ef-
fective medical-marijuana law when fifty-six percent of California vot-
ers approved ballot Proposition 215, codified as the Compassionate 
Use Act of 1996.
154
  Twelve states followed California’s lead and 
 
 147 MARIJUANA POLICY PROJECT, supra note 10, at 10. 
 148 Id. at 1. 
 149 Id. at 5. 
 150 See, e.g., ARIZ. REV. STAT. ANN. § 13-3412.01 (LEXIS through 2010 legislation); 
CONN. GEN. STAT. ANN. § 21a-246, § 21a-253 (LEXIS through 2010 legislation) (allow-
ing physicians to prescribe marijuana for chemotherapy or glaucoma); LA. REV. STAT. 
ANN. § 40:1046 (LEXIS through 2010 Reg. Sess.) (allowing physicians to prescribe 
marijuana for glaucoma, cancer chemotherapy and spastic quadriplegia); N.H. REV. 
STAT. ANN. § 318-B:9 (2010) (allowing physicians to prescribe marijuana for cancer 
chemotherapy and radiology); VA. CODE ANN. § 18.2-251.1 (LEXIS through 2010 
Reg. Sess.) (allowing physicians to prescribe marijuana for glaucoma and cancer). 
 151 See MARIJUANA POLICY PROJECT, supra note 10, at app. A-13–16.  In addition to 
the District of Columbia, the following states have re-scheduled marijuana at the 
state level: Iowa, Tennessee, Arkansas, Maine, New Mexico (only in regard to patients 
obtaining marijuana for medicinal purposes under the state Lynn and Erin Compas-
sionate Use Act), and Massachusetts.  See id. at app. A.  
 152 See United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 491 (2001); 
see also 21 U.S.C. § 829 (2006) (detailing how drugs classified in Schedules II through 
V may be prescribed and dispensed). 
 153 MARIJUANA POLICY PROJECT, supra note 10, at app. A-20.  These states include 
California, Michigan, Missouri, New Hampshire, New Mexico, Rhode Island, and 
Washington.  Id.  
 154 See NORML, supra note 1; see also CAL. HEALTH & SAFETY CODE § 11362.5 (West 
2007).  California’s medical marijuana law was amended in 2004 by the Medical Ma-
rijuana Program, codified as sections 11362.7–.9. 
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enacted medical-marijuana legislation between 1998 and 2008.
155
  In 
addition to California, medical-marijuana laws in Alaska, Colorado, 
Maine, Michigan, Montana, Nevada, Oregon, and Washington were 
enacted through the ballot-initiative process or by statewide referen-
dum.
156
  In June 2000, Hawaii was the first state to have its state legis-
lature enact its Medical Use of Marijuana Act
157
 rather than using a 
ballot initiative as previous states had done.
158
  New Mexico, Rhode 
Island, and Vermont soon followed Hawaii’s lead.
159
  While each state 
law varies in the protection that it provides, each has “removed state-
level criminal penalties for the cultivation, possession, and use of ma-
 
 155 See COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st 
Sess.); ALASKA STAT. §§ 17.37.010–.080, 11.71.090 (LexisNexis, LEXIS through 2010 
Reg. Sess.); COLO. REV. STAT. §§ 18-18-406.3, 25-1.5-106 (LEXIS through 67th Gen. 
Assembly, 1st Sess.); HAW. REV. STAT. §§ 329-121 to -128 (LexisNexis, LEXIS through 
2010 Reg. Sess.); ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS through 2009 2d 
Reg. Legis. Sess.); MICH. COMP. LAWS ANN. §§ 333.26421 to .26430 (LexisNexis, LEXIS 
through P.A. 383 of 2010 Leg. Sess.); MONT. CODE ANN. §§ 50-46-101 to -210 (Lexis-
Nexis, LEXIS through 2009 Reg. and Spec. Sess.); NEV. REV. STAT. §§ 453A.010 to 810 
(LexisNexis, LEXIS through 2010 Reg. Sess.); N.M. STAT. ANN. §§ 26-2B-1 to -7 (Lex-
isNexis, LEXIS through 2010 2d Spec. Sess.); OR. REV. STAT. §§ 475.300 to .375 
(LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-1 to -12 (LEXIS through 
Jan. 2010 Legis. Sess.); VT. STAT. ANN. tit. 18, §§ 4472 to 4474(d) (LEXIS through 
2010 Sess.); WASH. REV. CODE §§ 69.51A.005 to .902 (LexisNexis, LEXIS through 2010 
Reg. and 2d Spec. Sess.).  Maryland has also attempted to provide individuals in need 
of marijuana for medicinal purposes with some protection from criminal prosecution 
by allowing individuals to raise a defense of medical necessity for the use or posses-
sion of marijuana during sentencing.  See MD. CODE ANN., CRIM. LAW §§ 5-601(c), -
619(c) (LexisNexis, LEXIS through 2010 Reg. Sess.) (allowing defendants to raise a 
defense of medical necessity for marijuana use or possession and for possession or 
use of drug paraphernalia, respectively).  If use is proven, an individual is  subject to 
a fine not to exceed one-hundred dollars but is not be subjected to jail time.  See id.  
The law fails, however, to provide a defense for cultivation by a medical-marijuana 
user or their caregiver.  MARIJUANA POLICY PROJECT, supra note 10, at 1.  A necessity 
defense “gives defendants a chance to prove in court that their violation of the law 
was necessary to avert a greater evil.”  Id. at app. K-1.  In addition, on May 4, 2010, 
Washington, D.C. amended its law to allow the medical use of marijuana by patients 
suffering from select chronic illnesses.  See Ashley Southall, Washington, D.C., Approves 
Medical Use of Marijuana, N.Y. TIMES, May 4, 2010, at A17. 
 156 MARIJUANA POLICY PROJECT, supra note 10, at 1.  See also EDDY, supra note 46, at 
18.  Interestingly, since California enacted the first medical law via ballot initiative in 
1996, “voters have approved medical marijuana initiatives in every state where they 
have appeared on a ballot with the exception of South Dakota, where a medical mari-
juana initiative was defeated in 2006 by 52% of the voters.”  Id.  
 157 HAW. REV. STAT. §§ 329-121 to -128 (LexisNexis, LEXIS through 2010 Reg. 
Sess.) 
 158 See NORML, supra note 1; see also MARIJUANA POLICY PROJECT, supra note 10, at 
app. A-2.  
 159 See MARIJUANA POLICY PROJECT, supra note 10, at 1.  
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rijuana, if such use has been recommended by a medical doctor.”
160
  
Each also provides some type of protection for patients, their caregiv-
ers, and physicians.
161
 
C. The Interplay Between State Medical-Marijuana Laws and the CSA 
1. The CSA, Preemption, and States’ Continued 
Experimentation 
The CSA does not preempt state medical-marijuana laws because 
Congress did not intend to occupy the field of drug regulation when 
it enacted the CSA, and it sought to leave regulation of the practice 
of medicine to the states.  Further, thus far, no state law has been 
found to conflict with the federal law.
162
  In short, the state and feder-
al governments simultaneously occupy the field of drug regulation.  
Thus, while Congress enacts criminal drug laws as an exercise of its 
Commerce Clause power,
163
 states do so also pursuant to their police 
powers to enact legislation for the protection of the health of their 
citizens.
164
 
The Supreme Court has never explicitly ruled that the CSA 
preempts state medical-marijuana laws.
165
  Additionally, it has never 
invalidated a state medical-marijuana law.
166
  In Gonzales v. Raich, two 
California citizens sought “injunctive and declaratory relief prohibit-
ing the enforcement of the CSA” to the extent that it prevented the 
patients “from possessing, obtaining, or manufacturing” marijuana 
for their personal use under California’s Compassionate Use Act 
 
 160 EDDY, supra note 46, at 17. 
 161 See id.  
 162 As stated in a Congressional Research Service report prepared for Congress 
that reviewed and analyzed federal and state law policies regarding medical marijua-
na,   
[s]tates can statutorily create a medical use exception for botanical 
cannabis and its derivatives under their own, state-level controlled sub-
stances laws. At the same time, federal agents can investigate, arrest, 
and prosecute medical marijuana patients, caregivers, and providers in 
accordance with the federal Controlled Substances Act, even in those 
states where medical marijuana programs operate in accordance with 
state law. 
EDDY, supra note 46, at 4. 
 163 See supra note 134. 
 164 See U.S. CONST. amend. X.  This power is reserved by the states in the Tenth 
Amendment of the United States Constitution, which states, “The powers not dele-
gated to the United States by the Constitution, nor prohibited by it to the States, are 
reserved to the States respectively, or to the people.”  Id.   
 165 This observation is based on a Lexis search conducted in October 2009. 
 166 Id. 
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(CUA).
167
  While the Court held that Congress’s Commerce Clause 
authority “includes the power to prohibit the local cultivation and use 
of marijuana in compliance with California law,” it did not invalidate 
the state law.
168
  In fact, Gonzales “was not decided on preemption 
grounds,”
169
 and the Court’s holding “does not mean that the CUA is 
preempted by federal law.”
170
 
Although no lower court has addressed whether the CSA 
preempts state medical-marijuana laws in their entirety,
171
 two courts 
have held that specific portions of the CUA were not preempted by 
the CSA.
172
  In City of Garden Grove v. Superior Court, a California appel-
late court determined that in enacting the CSA, Congress “made it 
clear” that it had no intention of preempting the states “on the issue 
of drug regulation.”
173
  The court explained: 
Indeed, the CSA explicitly contemplates a role for the States in 
regulating controlled substances . . . .  It provides: “No provision 
of the CSA shall be construed as indicating an intent on the part 
of Congress to occupy the field in which that provision operates, 
including criminal penalties, to the exclusion of any State law on 
the same subject matter which would otherwise be within the au-
thority of the State, unless there is a positive conflict between the 
provision . . . and that State law so that the two cannot consistently 
stand together.”
174
 
 
 167 Gonzales v. Raich, 545 U.S. 1, 1 (2005). 
 168 See id. at 9.  
 169 City of Garden Grove v. Superior Ct., 68 Cal. Rptr. 656, 673 (Cal. Ct. App. 
2007).  The court stated:  
The upshot of Raich is that the federal government and its agencies 
have the authority to enforce the federal drug laws, even in a state like 
California that has sanctioned the use of marijuana for medicinal pur-
poses.  However, we do not read Raich as extending beyond this partic-
ular point, into the realm of preemption. 
Id. at 674. 
 170 Id. at 674.  In its discussion of Gonzales v. Raich, the court specifically stated that 
“the high court’s decision did not sound the death knell of the CUA in state court 
proceedings.”  Id. 
 171 This observation is based on a Lexis search conducted in October 2009. 
 172 City of Garden Grove, 68 Cal. Rptr. at 678 (“[F]ederal supremacy principles do 
not prohibit the return of marijuana to a qualified user whose possession of the drug 
is legally sanctioned under state law.”); County of San Diego v. San Diego NORML, 
81 Cal. Rptr. 3d 461, 481–83 (Cal. Ct. App. 2008) (holding that California medical-
marijuana identification card laws are not preempted by the CSA). 
 173 City of Garden Grove, 157 68 Cal. Rptr. at 675. 
 174 Id. (citing 21 U.S.C. § 903 (2006)) (internal citations and quotations omitted).  
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Thus, according to the court, “this express statement by Congress . . . 
gives the usual assumption against preemption additional force.”
175
  
Furthermore, the court stated that “Congress enacted the CSA to 
combat recreational drug abuse and curb drug trafficking,” and that 
“[i]ts goal was not to regulate the practice of medicine, a task that 
falls within the traditional powers of the states.”
176
  Ultimately, the 
court found that California’s CUA represents “a state statutory 
scheme that limits state prosecution for medical marijuana possession 
but does not limit enforcement of the federal drug laws.”
177
  This sce-
nario, according to the court, “simply does not implicate federal su-
premacy concerns.”
178
 
After the Supreme Court handed down its ruling in Gonzales, the 
Attorneys General from every state that had removed criminal penal-
ties for the medical use of marijuana responded that the decision 
would have little impact on the viability of the state laws.
179
  And since 
the ruling, “these laws have continued to provide near total protec-
tion for the sick and dying patients they are intended to protect.”
180
 
While the federal government has authority to enforce its laws 
throughout the United States, it has no authority to require states to 
enforce federal law or to “force states to have laws that are identical 
to federal law.”
181
  State medical-marijuana laws are not preempted by 
the CSA because they do not conflict with the federal law, and states 
may continue to enact medical-marijuana legislation.
182
 
2. The Obama Administration: A New Take on Federal 
Drug Law Enforcement 
The Obama administration has vowed to refrain from prosecut-
ing individuals who violate federal drug statutes if their actions are 
lawful under state law, a move that stands in stark contrast to the pol-
icies of both the Clinton and Bush administrations. 
 
 175 Id. (internal quotations omitted).  
 176 Id. (internal quotations omitted). 
 177 Id. at 676. 
 178 Id. at 676–77 (internal citations omitted).  
 179 See Implications of U.S. Supreme Court Medical Marijuana Ruling, MARIJUANA 
POLICY PROJECT, http://www.mpp.org/reports/gonzales-v-raich-the-impact.html (last 
visited Oct. 31, 2010).  
 180 Id.  
 181 MARIJUANA POLICY PROJECT, supra note 10, at 8. 
 182 See supra note 162.  
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Nevertheless, “the federal government still discourages research 
into the medicinal uses of smoked marijuana.”
183
  And federal law en-
forcement agencies can, and until the election of President Obama 
did, continue to enforce federal law against individuals acting under 
state exceptions for medical marijuana.
184
  Some of the first state med-
ical-marijuana laws were passed while President Bill Clinton was in of-
fice.
185
  Under his administration, Attorney General Janet Reno and 
Drug Czar Barry McCaffrey “vowed to enforce violations of federal 
drug laws, namely the CSA.”
186
  The Bush administration went even 
further, and federal agents raided medical-marijuana distributors that 
violated federal statutes notwithstanding the dispensaries’ com-
pliance with state law.
187
 
Even as a presidential candidate, Barack Obama expressed his 
opinion that “states should be allowed to make their own rules on 
medical marijuana.”
188
  He has also expressed the opinion that mari-
juana should be treated as a health issue rather than a criminal jus-
tice issue.
189
 President Obama’s position is that “federal resources 
should not be used to circumvent state laws.”
190
 
In February 2009, “in a break from prior policies,” the Obama 
administration announced “that federal officials would stop raiding 
dispensaries of medical marijuana authorized under state law.”
191
  
 
 183 Harris, supra note 9, at A1.   
 184 See infra notes 186–87 and accompanying text. 
 185 See NORML, supra note 1.  These include laws in California, Alaska, Washing-
ton, Maine, Nevada, Colorado and Hawaii.  Id.  
 186 Cathryn L. Blaine, Note, Supreme Court “Just Says No” to Medical Marijuana: A 
Look at United States v. Oakland Cannabis Buyers’ Cooperative, 39 HOUS. L. REV. 
1195, 1200 (2002) (citing Nicole Dogwill, Note, The Burning Question: How Will the 
United States Deal with the Medical-Marijuana Debate, 1998 DET. C.L. REV. 247, 253 n.38 
(1998) (discussing the federal government’s stance on Proposition 215 in derogation 
of the CSA)).  
 187 See id.  The effect was particularly felt by California as the first of the states to 
legalize medical marijuana.  Id. 
 188 Bob Egelko, U.S. to Yield Marijuana Jurisdiction to States, S.F. CHRON., Feb. 27, 
2009, at A1.   
 189 Id.   
During one campaign appearance, Obama recalled that his mother 
had died of cancer, and said that he saw no difference between doctor-
prescribed morphine and marijuana as pain relievers.  He told an in-
terviewer in March that it was “entirely appropriate” for a state to legal-
ize the medical use of marijuana “with the same controls as other drugs 
prescribed by doctors.”  
Id. 
 190 Id.  
 191 Brian Seltzer, A Popular Plant is Quietly Spreading Across TV Screens, N.Y. TIMES, 
Sept. 15, 2009, at C1.  
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Soon after, U.S. Attorney General Eric Holder reported the Justice 
Department’s new policy to only target drug traffickers that use dis-
pensaries as a front.
192  This shift is significant.  According to Graham 
Boyd, director of the American Civil Liberties Union drug law 
project, states were reluctant to effectuate their medical-marijuana 
laws because of the previous administrations’ policies.
193
  States can 
now implement their important health policies without interference 
from the federal government. 
True to the Obama administration’s earlier representations, on 
October 19, 2009, the Department of Justice issued a policy memo to 
the U.S. Attorneys in states with medical-marijuana laws advising 
them not to allocate federal resources to pursue individuals that are 
in “clear and unambiguous compliance” with state laws.
194
  The memo 
does not, however, foreclose the possibility that an individual acting 
in compliance with state law could face federal prosecution for viola-
tions of federal law, as it appears to leave prosecution to the discre-
tion of the individual U.S. Attorney.
195
  As observed by the New York 
Times, “The new stance was hardly an enthusiastic embrace of medical 
marijuana, or the laws that allow it in some states, but signaled clearly 
that the administration thought there were more important priorities 
for federal prosecutors.”
196
 
 
 192 David Johnston & Neil A. Lewis, Obama Administration to Stop Raids on Medical 
Marijuana Dispensers, N.Y. TIMES, Mar. 18, 2009, at A20.  But when a federal judge 
sentenced the owner of a marijuana dispensary in California to a year in prison in 
June 2009, some worried that the Obama administration’s promise was empty.  See 
Solomon Moore, Prison Term For a Seller of Medical Marijuana, N.Y. TIMES, June 12, 
2009, at A18.  According to the U.S. District Attorney for the Central District of Cali-
fornia, however, the owner had not been acting in compliance with state law, and Jus-
tice Department Spokesman Mathew Miller clarified that “as a general rule we are 
not prioritizing federal resources to go after individuals or organizations unless there 
is a violation of both federal and state law.”  Id.  Therefore, only if an individual vi-
olates the very state law that protects his federally prohibited action does he risk 
prosecution.   
 193 See Johnston & Lewis, supra note 192, at A20.  
 194 Memorandum on Investigations and Prosecutions in States Authorizing the 
Medical Use of Marijuana from David W. Ogden, Deputy Att’y Gen., U.S. Dep’t of 
Justice, to Selected United States Att’ys (Oct. 19, 2009), available at  
http://www.justice.gov/opa/documents/medical-marijuana.pdf. Noting that “the 
Department of Justice is committed to the enforcement of the Controlled Substances 
Act in all States” and that “[t]his guidance regarding resource allocation does not 
‘legalize’ marijuana or provide a legal defense to a violation of federal law,” the 
memo stated that it “is intended solely as a guide to the exercise of investigative and 
prosecutorial discretion.”  Id.  
 195 See id.  
 196 David Stout & Solomon Moore, U.S. Won’t Prosecute in States that Allow Medical 
Marijuana, N.Y. TIMES, Oct. 20, 2009, at A1.  The article notes that “[s]ome federal 
law enforcement officials opposed the administration’s position.”  Id.  
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3. State Medical-Marijuana Laws Protect Patients In Need 
State laws cannot protect individuals from federal prosecution, 
but they can offer considerable protection to patients.  State and lo-
cal law enforcement are responsible for about ninety-nine percent of 
marijuana-related arrests.
197
  The federal government has not prose-
cuted anyone living in the first thirteen states with effective medical-
marijuana laws for small amounts of marijuana.
198
  Thus, state law-
makers are in a position to afford patients almost absolute protection 
from prosecution related to medical-marijuana use. 
IV. THE NEW JERSEY COMPASSIONATE USE MEDICAL MARIJUANA ACT 
Until now, existing New Jersey law had failed to distinguish be-
tween medical and recreational use, possession, or distribution of 
marijuana.
199
  The NJCMA carves out a narrow exception for the me-
dicinal use of marijuana by individuals who continue to suffer from 
the symptoms of debilitating medical conditions despite available 
treatment options. 
A. An Overview of the NJCMA 
1. Purpose of the Act 
The NJCMA seeks to protect from arrest and prosecution se-
riously ill patients who use medical marijuana to “alleviate suffering 
from debilitating medical conditions.”
200
  The Act also seeks to protect 
physicians, caregivers, and authorized producers and distributors of 
the drug.
201
  This purpose reflects the Legislature’s determination 
that compassion dictates a distinction in the law’s treatment of those 
who use marijuana for medical purposes.
202
 
 
 197 MARIJUANA POLICY PROJECT, supra note 10, at app. R-1. 
 198 Id.  
 199 See N.J. STAT. ANN. §§ 2C:35-1 to -29, 2C:36-1 to -10 (West 2010).  
 200 N.J. STAT. ANN. § 24:6I-2(e) (West 2010). 
 201 Id.   
 202 See id.  In addition to the legislature’s determination that “[c]ompassion dic-
tates that a distinction be made between medical and non-medical uses of marijua-
na,” the New Jersey Legislature has found and declared the following: 
    a. Modern medical research has discovered a beneficial use for mari-
juana in treating or alleviating the pain or other symptoms associated 
with certain debilitating medical conditions, as found by the National 
Academy of Sciences’ Institute of Medicine in March 1999; 
    b. According to the U.S. Sentencing Commission and the Federal 
Bureau of Investigation, 99 out of every 100 marijuana arrests in the 
country are made under state law, rather than under federal law.  Con-
sequently, changing state law will have the practical effect of protecting 
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2. Registration, Eligibility, and Physician Requirements 
The Act requires the Department of Health and Senior Services 
(DHSS) to establish and maintain a confidential registry of qualifying 
patients and their primary caregivers.
203
  The DHSS must also issue 
identification cards to qualifying individuals after a verification pro-
cedure.
204
  For a patient and his or her primary caregiver
205
 to obtain 
 
from arrest the vast majority of seriously ill people who have a medical 
need to use marijuana; 
     c. Although federal law currently prohibits the use of marijuana, the 
laws of Alaska, California, Colorado, Hawaii, Maine, Michigan, Mon-
tana, Nevada, New Mexico, Oregon, Rhode Island, Vermont, and 
Washington permit the use of marijuana for medical purposes, and in 
Arizona doctors are permitted to prescribe marijuana.  New Jersey joins 
this effort for the health and welfare of its citizens;  
    d. States are not required to enforce federal law or prosecute people 
for engaging in activities prohibited by federal law; therefore, com-
pliance with this act does not put the State of New Jersey in violation of 
federal law; 
§ 24:6I-2. 
 203 Id. § 24:6I-4(a), (f).  All information submitted to the DHSS must be kept con-
fidential and may only be disclosed to select individuals who require the information 
for official purposes, including “authorized employees of State or local law enforce-
ment agencies, only as necessary to verify that a person who has engaged in the sus-
pected or alleged medical use of marijuana is lawfully in possession of a registry iden-
tification card.”  § 24:6I-4(f)(2).  Additionally, a qualifying patient’s patient-physician 
privilege is not waived by application for, or receipt of, an identification card.  § 
24:6I-4(g).   
 204 § 24:6I-4.  If the potential primary caregiver otherwise meets the requirements 
of the Act, a primary-caregiver application will be provisionally approved pending the 
results of a criminal-background check.  § 24:6I-4(b).  For a detailed discussion of the 
primary-caregiver criminal-background check procedures, see § 24:6I-4(c).  “The de-
partment shall approve or deny an application or renewal within 30 days of receipt of 
the completed application or renewal, and shall issue a registry identification card 
within five days of approving the application or renewal.”  § 24:6I-4(b).  The DHSS 
may only deny an application or renewal “if the applicant fails to provide the infor-
mation required . . . or if the department determines that the information was incor-
rect or falsified or does not meet the requirements of this act.”  Id.   Denial of an ap-
plication or renewal is a final agency decision, subject to judicial review.  Id. 
 205 “Qualifying patient” or “patient” is defined as “a resident of the State who has 
been provided with a certification by a physician pursuant to a bona fide physician-
patient relationship.”  Id. § 24:6I-3. A “primary caregiver” or “caregiver” is defined as  
a resident of the State who: (a) is at least 18 years old; (b) has agreed to 
assist with a registered qualifying patient’s medical use of marijuana, is 
not currently serving as a primary caregiver for another qualifying pa-
tient, and is not the qualifying patient’s physician; (c) has never been 
convicted of possession or sale of a controlled dangerous substance, 
unless such conviction occurred after the effective date of this act and 
was for a violation of federal law related to possession or sale of mariju-
ana that is authorized under this act; (d) has registered with the de-
partment pursuant to section 4 of this act, and has satisfied the crimi-
nal history record background check requirement of section 4 of this 
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registry identification cards, which are valid for two years,
206
 the pa-
tient must submit a signed “certification” from the patient’s physician 
that authorizes the patient to apply for registration to use marijuana 
medicinally.
207
  According to the Act, the patient and physician must 
be in a “bona fide physician-patient relationship,” which the NJCMA 
defines as “a relationship in which the physician has ongoing respon-
sibility for the assessment, care and treatment of a patient’s debilitat-
ing medical condition.”
208
  A certification cannot be obtained from a 
physician with whom the patient consults solely for the purpose of 
obtaining authorization for the medical use of marijuana.
209
  Only 
physicians licensed to practice medicine in New Jersey may provide 
certifications.
210
 
Additionally, to qualify under the NJCMA, patients and primary 
caregivers must be New Jersey citizens.
211
  Only those patients with a 
“debilitating medical condition” are eligible for protection under the 
NJCMA.  The Legislature has defined “debilitating medical condi-
tion” to mean: 
 
act; and (e) has been designated as primary caregiver on the qualifying 
patient’s application or renewal for a registry identification card or in 
other written notification to the department. 
Id.  It is important to note that “no applicant shall be disqualified from serving as a 
registered primary caregiver on the basis of any conviction disclosed by a criminal 
history record background check . . . if the individual has affirmatively demonstrated 
to the commissioner clear and convincing evidence of rehabilitation.”  § 24:6I-
4(c)(5).  
 206 § 24:6I-4(a). 
 207 § 24:6I-4(a)(1).  “Certification” is defined as “a statement signed by a physician 
with whom a qualifying patient has a bona fide physician-patient relationship, which 
attests to the physician’s authorization for the patient to apply for registration for the 
medical use of marijuana.”  § 24:6I-3.  In addition to a certification, a qualifying pa-
tient must submit an application or renewal fee (to be determined on a sliding 
scale); the name, address, and birth date of the patient and caregiver (if applicable); 
and the name, address and telephone number of the patient’s physician.  § 24:6I-
4(a)(2)–(4). 
 208 § 24:6I-3.   
 209 See id.  
 210 Id. § 24:6I-5(a).  “Physician” is defined as”: 
a person licensed to practice medicine and surgery pursuant to Title 45 
of the Revised Statutes with whom the patient has a bona fide patient 
physician-patient relationship and who is the primary care physician, 
hospice physician, or physician responsible for ongoing treatment of 
the patient’s debilitating medical condition, provided, however, that 
such ongoing treatment shall not be limited to the provision of autho-
rization for a patient to use medical marijuana or consultation solely 
for that purposes. 
§ 24:6I-3.   
 211 Id. 
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(1) one of the following  conditions, if resistant to conventional 
medical therapy: seizure disorder, including epilepsy; intractable 
skeletal muscular spasticity; or glaucoma; (2) one of the following 
conditions, if severe or chronic pain, severe nausea or vomiting, 
cachexia, or wasting syndrome results from the condition or 
treatment thereof: positive status for human immunodeficiency 
virus, acquired immune deficiency syndrome, or cancer; (3) 
amyotrophic lateral sclerosis, multiple sclerosis, terminal cancer, 
muscular dystrophy, or inflammatory bowl disease, including 
Crohn’s disease; (4) terminal illness, if the physician has deter-
mined a prognosis of less than 12 months of life; or (5) any other 
medical condition or its treatment that is approved by the [De-
partment of Health and Senior Services] by regulation.
212
 
Finally, the Act imposes heightened requirements when a quali-
fying patient is a minor.  Specifically, the NJCMA requires written 
consent to the medical use of marijuana from a parent or legal guar-
dian and a commitment from the parent to “control the acquisition 
and possession of the medical marijuana and any related parapherna-
lia.”
213
 
3. Alternative Treatment Centers and Marijuana Quantity 
The NJCMA authorizes patients and caregivers to obtain a pa-
tient’s supply of marijuana from a dispensary — an “alternative 
treatment center.”
214
  A patient may only register at one alternative 
treatment center at a time.
215
  The Act requires the DHSS to issue 
permits to alterative treatment centers and to ensure that the number 
of dispensaries throughout the state is sufficient to meet demand, in-
cluding a minimum of two facilities in northern, central, and south-
ern New Jersey.
216
  The first two permits issued in each of the three 
 
 212 Id.  
 213 § 24:6I-5(b) (defining the fiduciary as a “custodial parent, guardian, or person 
who has legal custody of the minor”).   
 214 § 24:6I-3.  The NJCMA defines “medical marijuana alternative treatment cen-
ter” or “alternative treatment center” as “an organization approved by the [DHSS] to 
perform activities necessary to provide registered qualifying patients with usable ma-
rijuana and related paraphernalia in accordance with the provisions of [the NJCMA]. 
This term shall include the organization’s officers, directors, board members, and 
employees.”  Id. 
 215 Id. § 24:6I-10(d). 
 216 Id. § 24:6I-7(a).  “The department shall approve or deny an application [for an 
alternative treatment center permit] within 60 days of receipt of the completed ap-
plication.”  § 24:6I-§ 7(e).  Denial of an application is a final agency decision, subject 
to judicial review.  Id.  A permit to operate as an alternative treatment center may be 
suspended or revoked for cause.  Id.  Such a revocation is also subject to judicial re-
view.  Id.   
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regions will be to non-profit entities; for-profit organizations are eli-
gible to apply thereafter.
217
  Precise permit eligibility requirements 
await the promulgation of regulations by the DHSS.
218
  To obtain a 
permit, however, every individual involved (including employees, of-
ficers, and directors of the centers) must undergo a criminal-
background check, for which the applicant must bear the cost.
219
  The 
DHSS will not issue permits to any person convicted of “a crime in-
volving any controlled dangerous substance or controlled substance 
analog” under New Jersey law or any similar state or federal law un-
less the conviction occurs after the NJCMA became effective and is 
for a violation of federal law related to possession or sale of medical 
marijuana.
220
 
The NJCMA authorizes the alternative treatment centers to ac-
quire and maintain a “reasonable” inventory, which the DHSS will de-
termine, “of marijuana seeds or seedlings and paraphernalia” and to 
grow, possess, and supply or sell the marijuana and related supplies 
to registered patients and their caregivers.
221
  Centers may charge for 
“the reasonable costs associated with marijuana production and dis-
tribution,” whether they operate on a nonprofit or for-profit basis.
222
 
To obtain marijuana from a dispensary under the Act, a patient 
or caregiver must provide the alternative treatment center with writ-
ten instructions from the patient’s certifying physician indicating the 
amount of marijuana that the patient requires over a thirty-day pe-
riod, which cannot exceed two ounces.
223
  A patient or primary care-
giver must also present his or her registry identification card, and the 
 
 217 § 24:6I-7(a). 
 218 § 24:6I-7(b).  
 219 § 24:6I-7(d)(1).  
 220 § 24:6I-7(c) (emphasis added).  Note, however, that no alternative treatment 
center employee will be disqualified “on the basis of any conviction disclosed” by a 
criminal-background check if the individual shows “clear and convincing evidence of 
rehabilitation.”  See § 24:6I-7(d)(6).  
 221 § 24:6I-7(a).  The Act establishes that alternative treatment centers may “pos-
sess, cultivate, plant, grow, harvest, process, display, manufacture, deliver, transfer, 
transport, distribute, supply, sell, or dispense marijuana, or related supplies to quali-
fying patients or their primary caregivers who are registered with the [DHSS].”  Id. 
 222 § 24:6I-7(h).  
 223 Id. § 24:6I-10(a). “A physician may provide a copy of a written instruction by 
electronic or other means, as determined by the commissioner, directly to an alter-
native treatment center on behalf of a registered, qualifying patient.”  § 24:6I-10(c).  
In the event that no amount is noted, no more than two ounces may be dispensed at 
one time.  § 24:6I-10(a).  In certain limited situations, a physician may issue multiple 
instructions at one time, authorizing the patient to receive a total of up to a ninety-
day supply.  § 24:6I-10(b).  
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center must verify and log all of the documentation.
224
  The DHSS 
must adopt regulations requiring the dispensaries to document care-
fully any pickup or delivery for patients.
225
 
4. Protections Provided by the Act 
“Medical use of marijuana” pursuant to the NJCMA means “the 
acquisition, possession, transport, or use of marijuana or parapherna-
lia by a registered qualifying patient as authorized by this act.”
226
  The 
Act does not allow patients to cultivate their own marijuana.  It does, 
however, provide patients, caregivers, alternative treatment centers, 
and physicians acting in conformity with the NJCMA with an affirma-
tive defense to criminal prosecution under New Jersey’s drug laws.
227
  
Additionally, such individuals will “not be subject to any civil or ad-
ministrative penalty, or denied any right or privilege, including, but 
not limited to, civil penalty or disciplinary action by a professional li-
censing board, related to the medical use of marijuana as authorized” 
by the Act.
228
 
The Act provides an explicit exemption from arrest and prosecu-
tion—rather than simply an affirmative defense to prosecution—in 
two instances.  First, individuals who are simply in the vicinity or pres-
ence of the authorized medical use of marijuana are not subject to 
arrest or prosecution.
229
  Second, parents or guardians are protected 
from arrest or prosecution “for assisting the minor in the medical use 
of marijuana as authorized” under the NJCMA.
230
 
The Act specifically notes that possession of, or application for, a 
registry card will not constitute probable cause for law enforcement 
 
 224 § 24:6I-10(c). The Act also notes that written physician instructions become 
void if marijuana is not dispensed pursuant to the instructions within one month.  Id.  
 225 § 24:6I-7(i)(1)–(2).  The regulations require written records of “each delivery 
of marijuana to, and pickup of marijuana for, a registered qualifying patient, includ-
ing the date and amount dispensed” be maintained by the alternative treatment cen-
ters “to ensure effective documentation of the operations of each alternative treat-
ment center.”  § 24:6I-7(i)(1).  
 226 Id. § 24:6I-3  
 227 Id. § 24:6I-6(b).  The Act provides this affirmative defense to prosecution un-
der Chapters 35 and 36 of New Jersey’s Code of Criminal Justice by amending N.J. 
STAT. ANN. § 2C:35-18 so that a qualifying patient, primary caregiver, physician, alter-
native treatment center—or any other person acting in accordance with the provi-
sions of the act—may raise an affirmative defense if he or she is in compliance with 
the NJCMA.  See § 2C:35-18.  A defendant claiming protection under the Act must 
prove the affirmative defense by a preponderance of the evidence.  Id. § 24:6I-12(a).  
 228 § 24:6I-6(b).  
 229 § 24:6I-6(e).  
 230 § 24:6I-6(f).  
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to search one’s person or property.
231
  Law enforcement is also not 
permitted to destroy marijuana possessed lawfully under the NJCMA, 
provided that the patient or primary caregiver is in possession of a 
registry identification card and no more marijuana than is statutorily 
allowed.
232
 
Finally, the Act provides that the State and its employees and 
agents shall be exempted from liability “for any deleterious out-
comes” that may result from a patient’s marijuana use.
233
  The Act 
does not explicitly provide the same protections for physicians or al-
ternative treatment centers. 
5. The NJCMA’s Sensible Limitations 
The Act places sensible limits on when and where a patient may 
engage in the medical use of marijuana.  For instance, patients may 
not operate a vehicle or heavy equipment “while under the influence 
of marijuana.”
234
  This restriction comports with medical evidence 
suggesting that marijuana may impair motor skills, attention, and 
reaction time.
235
  The NJCMA also restricts where a patient may 
smoke.  For instance, patients are prohibited from smoking marijua-
na on public transportation, in private cars while in operation, on 
school grounds, in public parks, beaches and recreational areas, in 
correctional facilities, and wherever New Jersey law otherwise prohi-
bits smoking generally.
236
  The Act seeks to ensure that a patient’s 
medical-marijuana use will not affect other people in public places. 
The NJCMA does not require governmental or private insurers 
to reimburse patients for medical-marijuana costs, and it does not re-
quire employers to accommodate marijuana use in any workplace.
237
  
The Act is silent, however, as to whether employers can fire or refuse 
to hire an individual for failing a drug test because of lawful marijua-
na use outside the workplace.  This has been an issue in other states, 
including Oregon, and courts have generally held that employers 
 
 231 § 24:6I-6(c).  
 232 § 24:6I-6(d).  
 233 Id. § 24:6I-15.  The Act also protects from liability for “any actions taken in ac-
cordance with” the NJCMA.  Id. 
 234 Id. § 24:6I-8(a).  
 235 AM. COLL. OF PHYSICIANS, supra note 56, at 6. 
 236 § 24:6I-8(b). 
 237 Id. § 24:6I-14.  Rhode Island is the only state that “specifically protects workers 
from being fired for their medical use of the drug.”  Courtney Rubin, Medical Mariju-
ana Laws Leave Employers Dazed and Confused, INC.COM (Feb. 12, 2010), 
http://www.inc.com/news/articles/2010/02/marijuana-law-confusing.html. 
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need not accommodate medical-marijuana use outside of the 
workplace.
238
 
The Act also makes it a crime to transfer or falsify registration 
cards or to present a false or altered card to law enforcement.
239
  This 
deters abuse of the registration system. 
6. Regulation, Reporting Requirements, and 
Implementation 
The NJCMA requires the Commissioner of the DHSS, in consul-
tation with the Department of Law and Public Safety, to “promulgate 
rules and regulations to effectuate” the Act’s purposes.
240
  The Act 
explicitly requires the DHSS to adopt regulations to “monitor, over-
see, and investigate all activities performed by an alternative treat-
ment center.”
241
  The Commissioner must also establish standards to 
“ensure adequate security of all facilities 24 hours per day, including 
production and retail locations, and security of all delivery methods 
to registered qualifying patients.”
242
 
The NJCMA also includes reasonable reporting requirements to 
detect abuse and ensure that the Act achieves its goal.  It mandates 
that both alternative-treatment centers and participating physicians 
furnish to the Director of the Division of Consumer Affairs in the 
Department of Law and Public Safety information for inclusion in a 
 
 238 See, e.g., Washburn v. Columbia Forest Prods. Inc., 104 P.3d 609, 616 (Or. Ct. 
App. 2005) (reversing a grant of summary judgment, the court stated that “concern 
about employees coming to work under the influence of marijuana might provide . . 
. justification for not accommodating [medical-marijuana use outside of the 
workplace]”).  
 239 See N.J. STAT. ANN. § 24:6I-9 (West 2010).  These criminal penalties supplement 
existing criminal law and are not intended to “limit prosecution or conviction for any 
other offense.”  Id. 
 240 Id. § 24:6I-16(a).  The Commissioner must also adopt interim regulations to 
implement the provisions of the Act within ninety days of the Act taking effect. § 
24:6I-16(b).  The regulations will be effective until the adoption of final rules, and 
regulations may be amended as necessary.  Id.  In terms of financing, the Act would 
allow the Commissioner of the DHSS to accept from any source grants or contribu-
tions to carry out the purpose of the Act.  Id. § 24:6I-11(a).  Additionally, any fees col-
lected pursuant to the Act, including qualifying patient or alternative treatment cen-
ter application fees, “shall be used to offset the cost of the department’s 
administration of the provisions of” the Act.  § 24:6I-11(b). 
 241 Id. § 24:6I-7(i)(2). 
 242 § 24:6I-7(i)(3). 
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monitoring system, as is required with other controlled dangerous 
substances under New Jersey law.
243
 
The Commissioner of the DHSS must inform the Governor and 
the Legislature of all actions that the Agency has taken to implement 
the Act’s mandates within one year of the Act’s effective date.
244
  In 
addition, the Commissioner has extensive annual reporting require-
ments, including: the number of registry applications, the number of 
registered patients and primary caregivers, the number of revoked 
cards, the nature of the reported conditions, the number of permits 
issued to and revoked from alternative treatment centers, and the 
number of participating physicians.
245
  Every two years, starting no lat-
er than two years after the Act’s effective date, the Commissioner 
must also report whether the state’s total number of alternative 
treatment centers and the maximum amount of marijuana allowed 
pursuant to the Act are sufficient to meet patients’ needs, in addition 
to reporting whether the alternative treatment centers are charging 
excessive prices.
246
  These reporting requirements will allow the state 
to assess the law’s effectiveness and make any necessary adjustments 
to it. 
Finally, while the NJCMA took effect on October 1, 2010, the 
DHSS Commissioner and the Director of the Division of Consumer 
Affairs were authorized to take administrative action in advance to ef-
fectuate the Act.
247
  This timing provision was intended to allow state 
officials to establish a proper infrastructure before the Act was im-
plemented. 
B. Critique of the Legislation 
Overall, the NJCMA is among the most restrictive medical-
marijuana laws in the nation because it provides considerable safe-
guards against abuse and diversion.  The Act does not conflict with 
federal law because it requires physicians to provide certifications ra-
 
 243 N.J. STAT. ANN. § 45:1-45.1(a); Id. § 45:1-45.  The information provided will be 
cross-referenced with the electronic system for monitoring controlled dangerous 
substances currently in existence in New Jersey.  See § 45:1-45.1(a).  
 244 Id. § 24:6I-12(a)(1).  
 245 Id.  
 246 § 24:6I-12(c). 
 247 S. 2105, 214th Leg., 2010–2011 Sess. (N.J. 2010).  It is important to note that 
while the Act was intended to take effect six months after enactment, the legislature 
approved an amendment to the Act in June 2010 that extended the effective date.  
See id.  
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ther than prescriptions,
248
 and it does not remove criminal penalties 
for violations of federal drug law.  More importantly, the NJCMA en-
sures that citizens of New Jersey who suffer from debilitating medical 
conditions will have legal access to medical marijuana that is highly 
regulated and extensively overseen by the DHSS.  Despite some room 
for improvement, New Jersey legislators have crafted a law that has 
the potential to both achieve its purpose of providing medical mari-
juana to patients in need and prevent exploitation of the system. 
1. Strengths of the NJCMA 
The registration requirement and issuance of identification 
cards are positive aspects of the Act and consistent with the policies of 
most other states with effective medical-marijuana legislation.
249
  
These safeguards allow New Jersey to track who has authorization to 
use medical marijuana or to assist in such use.  This, in turn, allows 
law enforcement to know if an individual is operating outside of the 
NJCMA.  The importance of such requirements is evident from ex-
amining states that have failed to implement them.  In Washington, 
for example, the lack of a patient registry makes it difficult to track 
the number of patients using marijuana legally.
250
  Additionally, be-
cause the state does not issue identification cards, law enforcement 
has had difficulty distinguishing between lawful and unlawful mariju-
ana users.
251
  “As a result, law enforcement varies throughout the state 
 
 248 Compare N.J. STAT. ANN. § 24:6I-5 (West 2010), with 21 U.S.C. §§ 812, 829 
(2006) (detailing how drugs classified in Schedules II through V may be prescribed 
and dispensed).  
 249 See, e.g., COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st 
Sess.); ALASKA STAT. §§ 17.37.030, .080 (LexisNexis, LEXIS through 2010 Reg. Sess.); 
HAW. REV. STAT. § 329-123 (LexisNexis, LEXIS through 2010 Reg. Sess.); MICH. COMP. 
LAWS ANN. § 333.26424 (LexisNexis, LEXIS through P.A. 383 of 2010 Leg. Sess.); 
MONT. CODE ANN. § 50-46-201 (LexisNexis, LEXIS through 2009 Reg. and Spec. 
Sess.); NEV. REV. STAT. § 453A.200 (LexisNexis, LEXIS through 2010 Reg. Sess.); N.M. 
STAT. ANN. § 26-2B-4 (LexisNexis, LEXIS through 2010 2d Spec. Sess.); OR. REV. STAT. 
§ 475.309 (LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-4 (2010); VT. 
STAT. ANN. tit. 18, § 4474(b) (LEXIS through Jan. 2010 Legis. Sess.).  Notably, howev-
er, some states that have registration programs allow patients and (or) caregivers to 
raise an affirmative defense to prosecution if they are not registered but otherwise in 
compliance with the requirements of the statute.  E.g., COLO. CONST. Art. XVIII § 
14LEXIS through 67th Gen. Assembly, 1st Sess.); MICH. COMP. LAWS ANN. § 333.26428 
(LexisNexis, LEXIS through P.A. 383 of 2010 Leg. Sess.); MONT. CODE ANN. § 50-46-
206 (LexisNexis, LEXIS through 2009 Reg. and Spec. Sess.); NEV. REV. STAT. § 
453A.310 (LexisNexis, LEXIS through 2010 Reg. Sess.); OR. REV. STAT. § 475.319 
(LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-8 (LEXIS through Jan. 
2010 Legis. Sess.). 
 250 MARIJUANA POLICY PROJECT, supra note 10, at app. F-14.  
 251 See id. 
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and several patients have been arrested or had their marijuana seized 
because police and patients have differing interpretations of the 
law.”
252
  Maine has experienced similar problems.
253
 
The Act also requires that the physician providing the patient’s 
certification be responsible for the ongoing treatment of the condi-
tion for which the patient requires the drug.
254
  Thus, a patient may 
not obtain a certification from a physician with whom the patient 
consulted solely to obtain authorization to use marijuana.
255
  This 
provision seeks to prevent abuse by reducing the likelihood that pa-
tients will obtain a certification when no real need exists.  In Califor-
nia, for instance, patients are only required to obtain an oral recom-
mendation from a physician to obtain medical marijuana.
256
  The 
problem, as evidence suggests, is that some physicians freely provide 
recommendations for medical marijuana—some even advertise their 
willingness to do so.
257
 
Another positive aspect of the NJCMA is that it allows patients to 
designate a primary caregiver to assist them in their use or acquisition 
 
 252 Id. at app. F-15.  In addition to proof of identity, patients in Washington are 
required to have “valid documentation,” which is defined as “a statement signed by a 
qualifying patient’s physician, or a copy of the qualifying patient’s pertinent medical 
records, which states that in the physician’s professional opinion, the patient may 
benefit from the medical use of marijuana.”  WASH. REV. CODE § 69.51A.010(5)(a), 
(b)(LexisNexis, LEXIS through 2010 Reg. and 2d Spec. Sess.).  Law enforcement has 
had difficulty determining what constitutes an appropriate doctor’s recommendation 
when confronting an individual claiming to be an authorized user.   MARIJUANA 
POLICY PROJECT, supra note 10, at app. F-15.    
 253 See MARIJUANA POLICY PROJECT, supra note 10, at app. F-1, F-10.  State authorities 
in Maine cannot track the number of patients legally using marijuana and law en-
forcement cannot discern lawful marijuana users from unlawful ones.  Id.  In addi-
tion, California has established a voluntary patient registry.  See CAL. HEALTH & SAFETY 
CODE § 11362.71 (Deering, LEXIS through 2010 legislation and 2011 Supp.).  Those 
who register are exempt from arrest and prosecution, while those who do not are ex-
empted only from arrest.  See id. 
 254 N.J. STAT. ANN. § 24:6I-3 (West 2010).  
 255 Id.  
 256 See CAL. HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legis-
lation and 2011 Supp.).  Notably, however, for citizens of California to obtain a vo-
luntary registration card that provides them with an exemption from arrest, heigh-
tened requirements must be satisfied.  See id. § 11362.715 (defining what is required 
to obtain an identification card, including written documentation from an “attend-
ing physician”); id. § 11362.7 (defining “attending physician” as, inter alia, “an indi-
vidual . . . who has taken responsibility for an aspect of the medical care, treatment, 
diagnosis, counseling, or referral of a patient and who has conducted a medical ex-
amination of hat patient”).  
 257 See Roger Parloff, How Marijuana Became Legal, FORTUNE (Sept. 18, 2009), 
http://money.cnn.com/2009/09/11/magazines/fortune/medical_marijuana_legali
zing.fortune/   
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of medical marijuana
258
 and provides the caregiver with the same pro-
tection from criminal liability as it does patients, physicians, and dis-
pensary operators.
259
  This is consistent with each of the thirteen med-
ical-marijuana laws currently in effect, which provide virtually the 
same protections to caregivers or “designated providers”
260
 that they 
do to patients.
261
  Considering that patients in need of marijuana are 
suffering from debilitating illnesses that could likely require caregiver 
assistance, caregiver protection is an important aspect of effective 
medical-marijuana legislation.  One potential deficiency in the New 
Jersey law is that a caregiver may only assist one patient at a time.
262
  
The requirement is arbitrary and a potential barrier to access for pa-
tients with no family or friends to serve as a caregiver.  The Act 
should permit professional caregivers to provide assistance to more 
than one patient at a time. 
Another positive aspect of the New Jersey law is that it allows pa-
tients to obtain marijuana from dispensaries.
263
  The establishment of 
state-licensed alternative treatment centers under the Act will make 
New Jersey the fourth state, in addition to New Mexico, Rhode Island, 
and Maine,
264
 to establish such strictly regulated medical marijuana 
 
 258 N.J. STAT. ANN. § 24:6I-3 (West 2010). 
 259 See supra note 227.   
 260 See, e.g., WASH. REV. CODE § 69.51A.010 )(LexisNexis, LEXIS through 2010 Reg. 
and 2d Spec. Sess.).   
 261 COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st Sess.); 
ALASKA STAT. §§ 17.37.030, 11.71.090 (LexisNexis, LEXIS through 2010 Reg. Sess.); 
CAL. HEALTH & SAFETY CODE § 11362.5, 11362.71(e) (Deering, LEXIS through 2010 
legislation and 2011 Supp.); COLO. REV. STAT. § 18-18-406.3 (LEXIS through 67th 
Gen. Assembly, 1st Sess.); HAW. REV. STAT. § 329-125 (LexisNexis, LEXIS through 
2010 Reg. Sess.); ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS through 2009 2d 
Reg. Legis. Sess.); MICH. COMP. LAWS ANN. §§ 333.26424, .26428 (LexisNexis, LEXIS 
through P.A. 383 of 2010 Leg. Sess.); MONT. CODE ANN. §§ 50-46-201, -206 (LexisNex-
is, LEXIS through 2009 Reg. and Spec. Sess.); NEV. REV. STAT. §§ 453A.200 (LexisNex-
is, LEXIS through 2010 Reg. Sess.); N.M. STAT. ANN. § 26-2B-4 (LexisNexis, LEXIS 
through 2010 2d Spec. Sess.); OR. REV. STAT. §§ 475.309 (LEXIS through 2009 Legis. 
Sess.); R.I. GEN. LAWS § 21-28.6-4 to -8 (LEXIS through Jan. 2010 Legis. Sess.); VT. 
STAT. ANN. tit. 18, § 4474(b) (LEXIS through 2010 Sess.); WASH. REV. CODE §§ 
69.51A.005 (LexisNexis, LEXIS through 2010 Reg. and 2d Spec. Sess.).     
 262 N.J. STAT. ANN. § 24:6I-3 (West 2010).   
 263 Id. § 24:6I-7(a).   
 264 See Abby Goodnough, A Setback in Maine for Gay Marriage, but Medical Marijuana 
Law Expands, N.Y. TIMES (Nov. 4, 2009), 
http://www.nytimes.com/2009/11/05/us/politics/05maine.html.  In contrast to the 
other three states, which each allow only non-profit dispensaries, only the first two al-
ternative treatment centers in each of the northern, central and southern regions of 
New Jersey must function as non-profit entities under the NJCMA.  § 24:6I-7(a).  Any 
other alternative treatment center approved by the DHSS may operate as either a 
non-profit or for-profit entity.  Id.   
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dispensaries.
265
  California, in contrast, does not require dispensaries 
to obtain licenses, which has resulted in a proliferation of dispensa-
ries and the alleged sale of marijuana to people who should not qual-
ify to receive the drug.
266
  Opponents of the NJCMA cite California as 
evidence that dispensaries cause serious abuse and diversion prob-
lems.
267
  The cannabis outlets in California, however, are not state-
licensed
268
 and are thus not regulated adequately by the state. 
In comparison, the NJCMA requires licensing, regulation, and 
extensive oversight of all alternative treatment centers throughout 
the state.
269
  This will ensure that New Jersey citizens have safe but 
controlled access to marijuana.  As discussed, the Act requires pros-
pective dispensary operators to obtain a permit from the DHSS.
270
  To 
do so, anyone involved in the operations of the center must undergo 
a criminal-background check.
271
  No one convicted of a crime involv-
ing any controlled dangerous substance under New Jersey law or a 
similar state or federal law would qualify for a permit.
272
  If, however, 
the conviction occurred after the NJCMA became effective and was 
for a violation of federal law related to medical marijuana, the person 
would qualify.
273
 
Additionally, unlike California dispensaries, New Jersey dispen-
saries are authorized to distribute marijuana only to patients or care-
 
 265 Goodnough, supra note 264.  California also allows marijuana cooperatives un-
der its medical marijuana laws, and Oregon allows for marijuana grow sites.  See CAL. 
HEALTH & SAFETY CODE § 11362.775 (Deering, LEXIS through 2010 legislation and 
2011 Supp.)(allowing collective or cooperative cultivation of marijuana by qualified 
persons); OR. REV. STAT. §§ 475.304 to .375 (LEXIS through 2009 Legis. 
Sess.)(providing for the regulation of marijuana grow sites where individuals are al-
lowed to grow marijuana for qualified patients). 
 266 Reports vary but they generally indicate that California has more than 700 
medical marijuana dispensaries throughout the state.  See, e.g., Parloff, supra note 
257.   
 267 See, e.g., Mary Pat Angelini, New Jersey Teens Will Do More Drugs Because We Lega-
lized Medical Marijuana, NEWJERSEYNEWSROOM.COM (Jan. 26, 2010), 
http://www.newjerseynewsroom.com/commentary/new-jersey-teens-will-do-more-
drugs-because-we-legalized-medical-marijuana. 
 268 See Clark Canfield, Maine Becomes 5th State to Allow Pot Dispensaries, ASSOCIATED 
PRESS, Nov. 5, 2009, available at http://abcnews.go.com/US/wireStory?id=8997909. 
 269 See N.J. STAT. ANN. § 24:6I-7 (West 2010). 
 270 § 24:6I-7(a). 
 271 § 24:6I-7(d). 
 272 § 24:6I-7(c).  Note, however, that no alternative treatment center employee will 
be disqualified “on the basis of any conviction disclosed” by a criminal background 
check if the individual shows clear and convincing evidence of rehabilitation.”  See § 
24:6I-7(d). 
 273 § 24:6I-7(c) (emphasis added). 
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givers who present both a registry identification card and written phy-
sician instructions that authorize a specific amount to be dispensed.
274
  
The NJCMA also requires centers to verify and log the patient’s do-
cumentation,
275
 which ensures that the DHSS will be able to monitor 
treatment centers’ distribution.  The added requirement that physi-
cians must report issuing patient certifications and written instruc-
tions to the Department of Law and Public Safety, and the inclusion 
of this information in a monitoring system,
276
 will also help to prevent 
abuse and diversion.  Furthermore, the Act allows patients to register 
at only one alternative treatment center at a time.
277
  This ensures that 
patients cannot circumvent the quantity limits imposed by the Act. 
The requirement that a physician provide written quantity in-
structions not only eliminates discretion on the part of the alternative 
treatment centers but also adds legitimacy to the proposed Act.  
While a physician cannot prescribe marijuana under federal law be-
cause it is a Schedule I substance,
278
 the written instruction require-
ment brings the process as close to prescribing as possible without vi-
olating federal law. 
The Act also requires the state to extensively regulate alternative 
treatment centers.  For instance, the DHSS would be responsible for 
establishing regulations for the approval and monitoring of all alter-
native treatment center activities.
279
  It would also set standards to en-
sure the security of the centers.
280
  This addresses opponents’ con-
cerns about “peripheral crime around these centers in the states that 
have them.”
281
 
Another positive aspect of the Act is that it clearly defines the 
maximum quantity of marijuana that patients are allowed to acquire 
at any given time.
282
  When California and Washington first enacted 
their medical-marijuana laws, neither state’s law adequately defined 
 
 274 Id. § 24:6I-10(c). 
 275 Id. 
 276 § 24:6I-10(a). 
 277 § 24:6I-10(d). 
 278 See 21 U.S.C. §§ 812, 829 (2006) (detailing how drugs classified in Schedules II 
through V may be prescribed and dispensed). 
 279 N.J. STAT. ANN. § 24:6I-7(b), (i) (West 2010). 
 280 § 24:6I-7(i). 
 281 See A804/S119 Passes Assembly Health & Senior Services Committee, COAL. FOR 
MEDICAL MARIJUANA – N.J., http://www.cmmnj.org/id13.htm (last visited Mar. 27, 
2011).  During the full General Assembly Health and Senior Services Committee 
Meeting on June 4, 2009, a representative from the New Jersey Fraternal Order of 
Police questioned how security would be handled at the centers.  See id. 
 282 § 24:6I-10(a). 
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the allowable quantity.
283
  This resulted in confusion among law en-
forcement that, at least in California, “sometimes err[ed] on the side 
of prosecuting—or at least hassling—patients if the quantity 
seem[ed] too large.”
284
  On the other hand, while it has the potential 
to prevent abuse and diversion, New Jersey’s limit, two ounces per 
thirty days,
285
 appears to be somewhat arbitrary and restrictive.  With-
out knowing the quality of the marijuana, arguing that the amount is 
inadequate is impossible.  But the limit is certainly among the smal-
lest quantities allowed in any of the states that have legalized medical 
marijuana.
286
  In addition, some state medical-marijuana laws have 
 
 283 California’s Compassionate Use Act did not define quantity at all.  See CAL. 
HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011 
Supp.).  In contrast, Washington’s Medical Use of Marijuana Act defined the quanti-
ty as “no more marijuana than is necessary for the patient’s personal, medical use, 
not exceeding the amount necessary for a sixty-day supply,” but it failed to define six-
ty-day supply.  See WASH. REV. CODE § 69.51A.040 (LexisNexis, LEXIS through 2010 
Reg. and 2d Spec. Sess.).  The “sixty-day supply” language was subsequently defined 
in October of 2008 as 24 ounces and 15 plants.  See WASH. ADMIN. CODE § 246-75-010 
(LEXIS through Aug. 2011); Medical Marijuana, WASH. STATE DEP’T OF HEALTH, 
http://www.doh.wa.gov/hsqa/medical-marijuana/(last visited Oct. 1, 
2011)[hereinafter Medical Marijuana Wash. State Dept.]; see also WASH. REV. CODE § 
69.51A.080 (LexisNexis, LEXIS through 2010 Reg. and 2d Spec. Sess.) (defining six-
ty-day supply, but noting that this amount is presumptive and can “be overcome with 
evidence of a qualifying patient’s necessary medical use”).  
 284 See MARIJUANA POLICY PROJECT, supra note 10, at app. F-15.     
 285 N.J. STAT. ANN. § 24:6I-10(a) (West 2010). 
 286 See, e.g., COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st 
Sess.)(allowing a patient to possess no more than two ounces of usable marijuana 
and six marijuana plants, but noting that an affirmative defense can be raised if the 
patient or caregiver is in possession of more when it is medically necessary); ALASKA 
STAT. § 17.37.040 (LexisNexis, LEXIS through 2010 Reg. Sess.) (“[A] patient, primary 
caregiver, or alternative caregiver may not . . . possess in the aggregate more than 
once ounce of marijuana in usable form; and six marijuana plants.”); CAL. HEALTH & 
SAFETY CODE § 11362.77 (Deering, LEXIS through 2010 legislation and 2011 
Supp.)(allowing a qualified patient or primary caregiver to possess “no more than 
eight ounces of dried marijuana” and “no more than six mature of twelve immature 
plants” per patient, but also noting that this amount can be overcome if a doctor de-
termines that the amount does not meet the patient’s need, and that counties or ci-
ties may increase the amount as they see fit); HAW. REV. STAT. § 329-121 (LexisNexis, 
LEXIS through 2010 Reg. Sess.) (stating that a qualifying patient and his or her care-
giver may possess jointly an “adequate supply” of marijuana, not to exceed three ma-
ture plants, four immature plants, and one ounce of usable marijuana per each ma-
ture plant); ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS through 2009 2d Reg. 
Legis. Sess.) (defining “usable amount of marijuana for medical use” as “2 1/2 
ounces or less of harvested marijuana . . . and a total of 6 plants”); MICH. COMP. LAWS 
ANN. § 333.26424 (LexisNexis, LEXIS through P.A. 383 of 2010 Leg. Sess.)(stating 
that a patient may possess no more than 2.5 usable ounces of marijuana and, if they 
have not designated a caregiver to grow for them, twelve plants kept in an enclosed, 
locked facility, and stating that at primary caregiver may possess no more than 2.5 
ounces of usable marijuana for each patient he cares for and no more than twelve 
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explicit quantity limits but allow a patient to raise an affirmative de-
fense at trial for possession of an unlawful quantity if the patient is 
otherwise in compliance with the statute.
287
  The Legislature should 
consider amending the NJCMA to include a similar provision; it 
could include an upper limit on the allowable amount to determine a 
fixed range it considers reasonable. 
2. Deficiencies, Unaddressed Issues, and Suggested 
Improvements 
Although the Act’s restrictiveness will help avoid abuse and di-
version, certain—and arguably over-restrictive—portions of the 
NJCMA threaten to prevent it from achieving its purpose by limiting 
the protections provided by the law and creating barriers to access. 
 
plants to be kept in an enclosed, locked facility); MONT. CODE ANN. § 50-46-201 (Lex-
isNexis, LEXIS through 2009 Reg. and Spec. Sess.) (stating that a patient and his ca-
regiver may not posses more than one ounce of usable marijuana and six marijuana 
plants each); NEV. REV. STAT. § 453A.200 (LexisNexis, LEXIS through 2010 Reg. Sess.) 
(stating that a patient or primary caregiver “may collectively possess, deliver or pro-
duce” no more than “one ounce of usable marijuana; three mature plants; and four 
immature plants,” but also providing an affirmative defense if patients or their care-
givers are in possession of a larger amount); N.M. STAT. ANN. §§ 26-2B-3 (LexisNexis, 
LEXIS through 2010 2d Spec. Sess.)(defining adequate supply to as “no more than 
reasonably necessary to ensure the uninterrupted availability of cannabis for a period 
of three months”); OR. REV. STAT. § 475.320 (LEXIS through 2009 Legis. Sess.) (“[A] 
registry identification cardholder or designated primary caregiver may possess up to 
six mature marijuana plants and 24 ounces of usable marijuana.”); R.I. GEN. LAWS § 
21-28.6-4 (LEXIS through Jan. 2010 Legis. Sess.)(stating that a patient may possess no 
more than twelve marijuana plants and two and a half ounces of usable marijuana 
and that a caregiver may not possess more than that amount for each patient she 
aids); VT. STAT. ANN. tit. 18, § 4472 (LEXIS through 2010 Sess.)(stating that a regis-
tered patient and their caregiver may collectively possess “no more than two mature 
marijuana plants, seven immature plants, and two ounces of usable marijuana”); 
WASH. ADMIN. CODE 246-75-010 (LexisNexis, LEXIS through 2010 Reg. and 2d Spec. 
Sess.) (defining sixty-day supply, and noting that this amount can be overcome based 
on the need of the patient); Medical Marijuana Wash. State Dept., supra note 283 (de-
fining “sixty-day supply” in October of 2008 as 24 ounces and 15 plants). 
It appears that currently in New Mexico patients/primary caregivers can possess 
six ounces of usable marijuana, and can either obtain marijuana through licensed 
non-profits (“cannabis production facilities”) within the state or apply to produce 
their own marijuana (four mature plants and twelve seedlings).  See Medical Cannabis 
Program Frequently Asked Questions, N.M. DEP’T OF HEALTH, 
http://nmhealth.org/idb/mcp_faq.shtml (last visited Mar. 27, 2011).  The non-
profits may be in possession of up to ninety-five mature plants and seedlings, as well 
as usable inventory to service the patients in the program.  See id. 
 287 See, e.g., NEV. REV. STAT. § 453A.310 (LexisNexis, LEXIS through 2010 Reg. 
Sess.)(providing an affirmative defense to patients and primary caregivers in posses-
sion of more than the allowed quantity of marijuana if that person “proves by a pre-
ponderance of the evidence that the greater amount is medically necessary as deter-
mined by the person’s (or assisted person’s) attending physician to mitigate the 
symptoms or effects of the person’s chronic or debilitating medical condition.”). 
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One significant deficiency of the NJCMA is that it exempts pa-
tients, primary caregivers, dispensary operators, and physicians from 
criminal liability but not from arrest or prosecution; the Act allows 
them only to raise an affirmative defense to prosecution.
288
  Only par-
ents or guardians assisting minors under the Act receive exemption 
from arrest or prosecution.
289
  This appears to be inconsistent with 
the Act’s stated purpose of protecting patients, caregivers, physicians, 
and dispensary operators from arrest and prosecution.
290
  The distinc-
tion is that while the Act protects these individuals from criminal lia-
bility if they prove compliance with the Act by a preponderance of 
the evidence,
291
 they would not necessarily escape the trauma of arrest 
and prosecution.  The other thirteen states vary in the protection that 
they provide from criminal liability.  California, for instance, provides 
an exemption from prosecution to unregistered patients who comply 
with its medical-marijuana laws, but an exemption from both arrest 
and prosecution to registered patients.
292
  Vermont provides an ex-
emption from arrest and prosecution to all registered patients in 
compliance with the statute.
293
  Montana provides an exemption from 
arrest and prosecution if a patient is registered, but it also allows un-
registered patients to raise an affirmative defense if they are other-
wise in compliance with the law.
294
  Alaska’s law, like the NJCMA, only 
provides patients with an affirmative defense.
295
 
The Legislature should amend the NJCMA to explicitly exempt 
the aforementioned individuals from arrest and prosecution when 
they act in compliance with the law.  No reason exists for patients au-
thorized to use marijuana for the treatment of a debilitating medical 
condition to go through the process of arrest and prosecution if they 
are in compliance with the law.  Physicians may be reluctant to pro-
vide patients with certifications if they are not exempted from arrest 
and prosecution.  Likewise, caregivers might be hesitant to provide 
assistance to patients.  These results are inconsistent with the Act’s 
purpose. 
 
 288 See supra note 227.   
 289 N.J. STAT. ANN. § 24:6I-6(f) (West 2011).  
 290 Id. § 24:6I-2(e) (emphasis added).  
 291 See supra note 227. 
 292 CAL. HEALTH & SAFETY CODE §§ 11362.5, 11362.71(e)–(f) (Deering, LEXIS 
through 2010 legislation and 2011 Supp.). 
 293 VT. STAT. ANN. tit. 18, § 4474b(a) (LEXIS through 2010 Sess.). 
 294 MONT. CODE ANN. §§ 50-46-201, -206 (LexisNexis, LEXIS through 2009 Reg. 
and Spec. Sess.). 
 295 ALASKA STAT. § 17.37.030 (LexisNexis, LEXIS through 2010 Reg. Sess.). 
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In lieu of, or in addition to amending the Act, the DHSS or the 
Attorney General should issue guidance to state and local law en-
forcement directing them to use discretion in investigating a claim of 
medical-marijuana use and encouraging arrest only if the patient, ca-
regiver, or operator is not in possession of a valid ID card or permit 
or if they are unable to verify the patient’s lawful registration.  Cali-
fornia has done this.
296
 
The Legislature should also consider allowing patients who are 
unregistered but otherwise in compliance with the law to raise an af-
firmative defense at trial, which Montana has done.
297
  This would cer-
tainly require a balancing of the risks and benefits.  As the law cur-
rently stands, because all patients are required to register with the 
DHSS
298
 and because of the extensive tracking of patient certifications 
and physician instructions by the DHSS and the Department of Law 
and Public Safety,
299
 the state will be able to track exactly who is re-
ceiving medical marijuana, how much they are receiving, who is re-
commending it, and who is distributing it.  This will help prevent 
abuse and diversion.  But if registering deters patients from obtaining 
the drug, perhaps providing an affirmative defense to prosecution to 
those not registered but otherwise in compliance would ensure that 
the Legislature is achieving its stated purpose of protecting “patients 
who use marijuana to alleviate suffering from debilitating medical 
conditions.”
300
 
Another arguable deficiency of the NJCMA is that it fails to cover 
serious health ailments.  The definition of “debilitating medical con-
dition” excludes severe or chronic pain (except pain caused by 
HIV/AIDS or cancer) as a qualifying condition.
301
  “Nearly half of all 
current physician recommendations for marijuana therapy are for 
chronic pain,” with chronic pain affecting about one in five Ameri-
 
 296 OFFICE OF THE ATTORNEY GEN., CALIF. DEP’T OF JUSTICE, GUIDELINES FOR THE 
SECURITY AND NON-DIVERSION OF MARIJUANA GROWN FOR MEDICAL USE (Aug. 2008), 
available at 
http://ag.ca.gov/cms_attachments/press/pdfs/n1601_medicalmarijuanaguidelines.
pdf.  
 297 See MONT. CODE ANN. §§ 50-46-201, -206 (LexisNexis, LEXIS through 2009 Reg. 
and Spec. Sess.). 
 298 N.J. STAT. ANN. § 24:6I-4(a) (West 2010). 
 299 Id. § 24:6I-11. 
 300 Id. § 24:6I-2(e). 
 301 See id. § 24:6I-3.   
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cans.
302
  The Coalition for Medical Marijuana New Jersey has criticized 
the law’s failure to help so many people suffering from severe or 
chronic pain.
303
  Nearly every other state medical-marijuana law allows 
patients suffering from chronic or severe pain to obtain the drug.
304
 
But the NJCMA does appear to provide marijuana to patients 
with some of the most debilitating illnesses, including any terminal 
illness that results in a prognosis of less than one year to live.
305
  The 
Act’s restrictive definition prevents abuse and helps ensure that only 
patients with legitimate needs obtain marijuana.  It stands in stark 
contrast to California’s Compassionate Use Act, which includes an 
expansive catchall provision; in California, qualifying conditions in-
clude “any other illness for which marijuana provides relief.”
306
  While 
initially restrictive, New Jersey’s law allows the DHSS to approve, by 
regulation, “any other medical condition or its treatment.”
307
  There-
fore, the definition can expand to provide access to more patients 
based on need over time. 
Another potential drawback of the Act is its failure to permit pa-
tients to cultivate their own marijuana.  The NJCMA allows patients to 
acquire, possess, or transport marijuana, but they may not grow it.
308
  
New Jersey will be the only state with a medical-marijuana law that 
penalizes patients for growing their own marijuana.
309
  While this may 
prevent abuse, it is also a potential barrier to access for patients. 
 
 302 Ken Wolski, The New Jersey Compassionate Use Medical Marijuana Act., COALITION 
FOR MED. MARIJUANA N.J. (July 21, 2009, 11:27 AM), 
http://cmmnj.blogspot.com/2009/09/new-jersey-compassionate-use-medical.html. 
 303 Id.  
 304 See, e.g., COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st 
Sess.); ALASKA STAT. § 17.37.070 (LexisNexis, LEXIS through 2010 Reg. Sess.); CAL. 
HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011 
Supp.); HAW. REV. STAT. § 329-121 (LexisNexis, LEXIS through 2010 Reg. Sess.); 
MICH. COMP. LAWS ANN. § 333.26423 (LexisNexis, LEXIS through P.A. 383 of 2010 
Leg. Sess.); MONT. CODE ANN. § 50-46-102 (LexisNexis, LEXIS through 2009 Reg. and 
Spec. Sess.); NEV. REV. STAT. § 453A.050 (LexisNexis, LEXIS through 2010 Reg. Sess.); 
OR. REV. STAT. § 475.302 (LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-3 
(LEXIS through Jan. 2010 Legis. Sess.); VT. STAT. ANN. tit. 18, § 4472 (LEXIS through 
2010 Sess.); WASH. REV. CODE § 69.51A.010 (LexisNexis, LEXIS through 2010 Reg. 
and 2d Spec. Sess.).  But see ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS 
through 2009 2d Reg. Legis. Sess.).  
 305  See N.J. STAT. ANN. § 24:6I-3 (West 2010). 
 306 CAL. HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legisla-
tion and 2011 Supp.). 
 307 N.J. STAT. ANN. § 24:6I-3 (West 2010). 
 308 Id.  
 309 EDDY, supra note 46, at 18.  
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In California, federal authorities have “raided more than 190 
medical marijuana locations, mostly dispensaries,”
310
 and after Cali-
fornia enacted its medical-marijuana law, the United States sued to 
enjoin a non-profit California dispensary from distributing the drug 
on the grounds that the cooperative’s activities violated the CSA.
311
  In 
United States v. Oakland Cannabis Buyer’s Coop., the Supreme Court 
held that no medical-necessity defense exception to the CSA’s prohi-
bition on marijuana manufacturing and distribution exists.
312
  Thus, 
federal authorities could shut down any New Jersey alternative treat-
ment center and prevent qualified patients from obtaining marijua-
na.  In contrast to New Jersey, California allows patients to cultivate 
their own marijuana.
313
  Therefore, the closure of dispensaries in Cali-
fornia would be less problematic for patients because they could 
simply grow their own marijuana. 
The NJCMA also requires a patient’s certifying physician to be 
licensed to practice medicine in New Jersey.
314
  This requirement fo-
recloses a patient’s ability to seek the care of a specialist in a neigh-
boring state.  Patients should be free to seek the best care possible.  
Vermont, for example, allows patients to seek the care of physicians 
licensed in other states, including New Hampshire, Massachusetts, 
and New York.
315
  New Jersey should similarly respect patient choice 
and allow patients to seek the treatment of out-of-state doctors. 
The NJCMA should also include two additional provisions.  First, 
the Legislature should consider giving registry identification cards 
from other states full force and effect, as Montana, Rhode Island, and 
Michigan have done.
316
  Compassion dictates that no patient using 
marijuana should face criminal penalties in New Jersey if the patient 
received proper authorization to use marijuana in another state and 
is in possession of valid documentation.  Second, the law should not 
interfere with a patient’s parental or custodial rights; unless the par-
ent presents a danger to the child, using medical marijuana in accor-
 
 310 MARIJUANA POLICY PROJECT, supra note 10, at app. F-17. 
 311 United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 486–87 
(2001). 
 312 Id.  
 313 CAL. HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legisla-
tion and 2011 Supp.). 
 314 N.J. STAT. ANN. § 24:6I-3 (West 2010).   
 315 VT. STAT. ANN. tit. 18, § 4472 (LEXIS through 2010 Sess.). 
 316 MICH. COMP. LAWS ANN. §§ 333.26423–.26424 (LexisNexis, LEXIS through P.A. 
383 of 2010 Leg. Sess.); MONT. CODE ANN. § 50-46-201 (LexisNexis, LEXIS through 
2009 Reg. and Spec. Sess.); R.I. GEN. LAWS ANN. § 21-28.6-4 (LEXIS through Jan. 2010 
Legis. Sess.). 
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dance with the Act should not affect the parent-child relationship.  
Thus, the Act should include the following provision, modeled after 
Michigan’s law: “A person shall not be denied custody or visitation of 
a minor for acting in accordance with this act, unless the person’s 
behavior is such that it creates an unreasonable danger to the minor 
that can be clearly articulated and substantiated.”
317
  We must not 
force individuals suffering from debilitating illnesses to choose be-
tween relief and their children. 
Finally, the NJCMA does not expressly deal with a number of 
important issues, which the regulations promulgated by the DHSS 
should address.  The Act is silent as to how and from what sources al-
ternative treatment centers would obtain marijuana or marijuana 
seeds or seedlings and where the centers’ marijuana would be grown.  
It also places no limits on where alternative treatment centers may be 
located.  Whether the DHSS will impose any zoning limits, such as a 
requirement that centers be located at a specified minimum distance 
from residential areas or schools, remains to be seen.  The NJCMA 
also does not explicitly require the DHSS to establish methods for 
testing and guaranteeing the quality and safety of marijuana sold at 
alternative treatment centers.  To ensure that patients have access to 
unadulterated, good-quality marijuana, this issue must be addressed 
by the DHSS.  With respect to cost, the Act only specifies that a center 
may charge “for the reasonable costs associated with the production 
and distribution of marijuana.”
318
  Every two years, the DHSS must 
evaluate whether centers are charging “excessive prices.”
319
  The 
DHSS should prevent costs from serving as a barrier to patient access. 
During the drafting process, New Jersey lawmakers expressed 
their intention to make the law restrictive enough so that only pa-
tients in serious need could obtain marijuana.
320
  They did not want to 
encourage illegal drug use.
321
  But at the opposite end of the spec-
trum, the law should not be so restrictive that it fails to serve the pur-
pose for which it was intended—to provide medical marijuana to pa-
tients in need.  As drafted, the NJCMA generally provides the 
necessary balance.  The aforementioned proposed amendments 
 
 317 See MICH. COMP. LAWS ANN. § 333.26424 (LexisNexis, LEXIS through P.A. 383 
of 2010 Leg. Sess.). 
 318 N.J. STAT. ANN. § 24:6I-7(h) (West 2010). 
 319 Id. § 24:6I-14(c). 
 320 See Chris Megarian & Susan K. Livio, Making Sure Medical Marijuana Can Be 
Used, but Not Abused, STAR LEDGER, June 7, 2009, at 17.  
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would also strengthen the protections provided by the Act and help 
prevent abuse of the system. 
V. CONCLUSION 
The legalization of medical marijuana will provide New Jersey 
citizens with legal access to a drug that is safe and effective in sooth-
ing the symptoms of debilitating medical conditions.  For a subset of 
patients, botanical marijuana may be the only option for relief.  Be-
cause marijuana remains a Schedule I controlled substance under 
federal law, New Jersey must act to ensure that patients with debilitat-
ing conditions avoid prosecution for using marijuana medicinally.  
The extensive state regulation, the prohibition of marijuana cultiva-
tion, and the limited definition of debilitating illness make New Jer-
sey’s law the most restrictive in the nation.  But in addition to pre-
venting abuse and diversion, the NJCMA will provide access to the 
drug to patients with the greatest need.  Compassion, reason, and 
medical evidence require that we distinguish between the medical 
and recreational use of marijuana under the law.  As of January 18, 
2010, this distinction now exists in New Jersey. 
 
